Treatment for Danon disease

JP2023552443A5Pending Publication Date: 2024-11-19SPACECRAFT SEVEN LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023534292
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-07
Filing Date
2021-12-07
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

There is a need for effective methods and compositions to treat Danon's disease, a familial cardiomyopathy associated with impaired autophagy due to loss-of-function mutations in the LAMP-2 gene, particularly focusing on increasing LAMP-2 protein expression to mitigate oxidative stress and apoptotic cell death.

Method used

Administration of a recombinant adeno-associated virus (rAAV) virion containing a vector genome encoding the LAMP-2B protein, optionally combined with immunomodulatory agents like tacrolimus, rituximab, and eculizumab, to enhance LAMP-2B expression in cardiomyocytes and skeletal muscle, thereby correcting autophagic abnormalities and improving cardiomyocyte function.

Benefits of technology

The approach leads to increased LAMP-2B expression, reducing oxidative stress and apoptotic cell death, correcting histological abnormalities, and improving cardiac function in patients with Danon's disease.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Methods are provided for treating Danon disease in a subject identified as having or at risk for Danon disease and / or identified as having an inactivating mutation in one or more isoforms of the LAMP-2 gene, which may include administering to the subject a therapeutically effective amount of a recombinant adeno-associated virus (rAAV) virion comprising a capsid and a vector genome, wherein the vector genome comprises a polynucleotide sequence encoding a LAMP-2 protein, preferably a LAMP-2B protein.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Patent Application No. 63 / 122,249, titled "Treatment of Danon Disease," filed on 7 December 2020, which is incorporated herein by reference in its entirety.

[0002] Sequence List This application was filed electronically via EFS-Web and includes an electronically submitted sequence listing in .txt format. This .txt file contains a sequence listing titled "ROPA_023_01WO_SeqList_ST25.txt", created on December 7, 2021, and approximately 62 kilobytes in size. The sequence listing contained in this .txt file is part of this specification and is incorporated herein by reference in its entirety.

[0003] Field of Invention This invention relates, in general terms, to the clinical use of adeno-associated virus (AAV) gene therapy in Danon disease. [Background technology]

[0004] Lysosomal-associated membrane protein 2 (LAMP-2, also known as CD107b) is a gene that encodes a lysosomal-associated membrane glycoprotein. Alternative splicing of this gene produces three isoforms: LAMP-2A, LAMP-2B, and LAMP-2C. Loss-of-function mutations in LAMP-2 are associated with human diseases, including Danon disease, a familial cardiomyopathy associated with autophagy dysfunction.

[0005] International Patent Application Publication No. 2017 / 127565A1 (Patent Document 1) discloses, as described in Hashem, et al., Stem Cells. 2015 Jul;33(7):2343-50 (Non-Patent Document 1), that overexpression of LAMP-2 in human induced pluripotent stem cells (hiPSCs) derived from patients with LAMP-2 mutations leads to a reduction in oxidative stress levels and apoptotic cell death, thus confirming the importance of LAMP-2B in disease pathophysiology.

[0006] There remains a need in the art for methods and compositions related to the treatment of Danon disease in human subjects. This disclosure provides such methods and compositions. [Prior art documents] [Patent Documents]

[0007] [Patent Document 1] International Patent Application Publication No. 2017 / 127565A1 [Non-patent literature]

[0008] [Non-Patent Document 1] Hashem,et al.,Stem Cells.2015 Jul;33(7):2343-50 [Overview of the Initiative]

[0009] In one embodiment, the Disclosure provides a method for treating Danon disease in subjects who have been identified as having or being at risk of Danon disease, and / or who have been identified as having an inactivating mutation in one or more isoforms of the LAMP-2 gene, the method comprising administering a therapeutically effective dose of recombinant adeno-associated virus (rAAV) virion comprising a capsid and a vector genome, wherein the vector genome comprises a polynucleotide sequence encoding the LAMP-2 protein, preferably the LAMP-2B protein.

[0010] In some embodiments, the therapeutically effective dose is approximately 2 × 10⁻¹⁶ per kilogram (kg) of the subject's body weight. 14 It is less than a vector genome (vg).

[0011] In some embodiments, the therapeutically effective dose is approximately 1.5 × 10⁻¹⁴ per kg of the subject's body weight. 14 It is less than vg.

[0012] In some embodiments, the therapeutically effective dose is approximately 1 × 10¹⁶ units per kg of the subject's body weight. 14 It is less than vg.

[0013] In some embodiments, the therapeutically effective dose is at least about 1 × 10¹⁶ per kg of the subject's body weight. 12 It is vg.

[0014] In some embodiments, the therapeutically effective dose is at least about 1 × 10¹⁶ per kg of the subject's body weight. 13 It is vg.

[0015] In some embodiments, the therapeutically effective dose is approximately 6.7 × 10⁶ per kg of the subject's body weight. 13 It is vg.

[0016] In some embodiments, the therapeutically effective dose is approximately 1.1 × 10⁻¹⁴ per kg of the subject's body weight. 14 It is vg.

[0017] In some embodiments, the therapeutically effective dose is approximately 2.0 × 10⁶ per kg of the subject's body weight. 14 It is vg.

[0018] In some embodiments, the method further comprises administering an effective amount of tacrolimus to the target.

[0019] In some embodiments, the method further includes administering an effective dose of rituximab to the target.

[0020] In some embodiments, the method includes administering an effective amount of tacrolimus to a target and administering an effective amount of rituximab to a target.

[0021] In some embodiments, the method includes administering an effective dose of eculizumab to the target.

[0022] In some embodiments, the method further includes administering an effective dose of rituximab, an effective dose of tacrolimus, and / or an effective dose of eculizumab.

[0023] In some embodiments, subjects are at risk of developing complement activation complications such as atypical hemolytic uremic syndrome (aHUS), and optionally, reversible thrombocytopenia and / or acute kidney injury (AKI).

[0024] In some embodiments, the method further comprises administering an effective amount of corticosteroid to the target.

[0025] In some embodiments, the method further comprises administering an effective amount of corticosteroid to the target before administering an effective amount of tacrolimus.

[0026] In some embodiments, the subjects are selectively young people aged 8–14 and / or 15–17 years.

[0027] In some embodiments, the subjects are optionally selected to be children aged 0–8 years.

[0028] In some embodiments, the subjects are optionally adults aged 18 or older.

[0029] In some embodiments, a therapeutically effective dose of AAV is administered intravenously.

[0030] In some embodiments, a therapeutically effective dose of AAV is administered by direct cardiac injection, or optionally by an intrajugular vein catheter or a Swan-Ganz catheter.

[0031] In some embodiments, a therapeutically effective dose of AAV is administered by intraperitoneal injection.

[0032] In some embodiments, the method results in one or more of the following: a) transduction of cardiomyocytes and / or skeletal muscle by AAV; b) selective expression of exogenous ribonucleic acid polynucleotide encoding LAMP-2B and / or expression of exogenous LAMP-2B protein in cardiomyocytes and / or skeletal muscle; c) correction or improvement of one or more Danon disease-related histological abnormalities, selectively autophagocytic vacuoles or myofibrils; d) correction or improvement of cardiomyocyte molecular marker expression; and / or e) correction or improvement of cardiomyocyte histology.

[0033] In some embodiments, the AAV comprises an expression cassette containing a polynucleotide sequence encoding a LAMP-2B protein operably linked to a promoter, wherein the polynucleotide sequence shares at least 95% identity with SEQ ID NO: 2, and / or the LAMP-2B protein shares at least 95% identity with SEQ ID NO: 1.

[0034] In some embodiments, the polynucleotide sequence includes or consists of SEQ ID NO: 2, and / or the LAMP-2B protein includes or consists of SEQ ID NO: 1.

[0035] In some embodiments, the promoter is a CAG promoter.

[0036] In some embodiments, the promoter includes an enhancer / promoter region that shares at least 95% identity with SEQ ID NO: 22.

[0037] In some embodiments, the enhancer / promoter region includes or consists of SEQ ID NO: 22.

[0038] In some embodiments, the expression cassette is arranged in the order from 5′ to 3′. (a) Enhancer / promoter region including Sequence ID No. 22, (b) The polynucleotide sequence comprising Sequence ID No. 3, which encodes the LAMP-2B protein, (c) A 3′ UTR sequence containing sequence number 27, and / or (d) Polyadenylated sequence containing sequence number 7 Includes.

[0039] In some embodiments, the expression cassette is adjacent to (i) a 5′ ITR containing SEQ ID NO: 11 and (ii) a 3′ ITR containing SEQ ID NO: 12.

[0040] In some embodiments, the expression cassette includes sequence number 8.

[0041] In some embodiments, the capsid is an AAV9 capsid.

[0042] In some embodiments, the AAV9 capsid comprises one or more capsid proteins containing amino acids 1-736 of SEQ ID NO: 28, amino acids 138-736 of SEQ ID NO: 28, or amino acids 203-736 of SEQ ID NO: 28.

[0043] In other embodiments, the Disclosure provides a unit dose, pharmaceutical composition, or composition for use in the treatment of Danon disease. The unit dose, pharmaceutical composition, or composition for use comprises a therapeutically effective amount of recombinant adeno-associated virus (rAAV) virion comprising a capsid and a vector genome, wherein the vector genome comprises a polynucleotide sequence encoding a LAMP-2 protein, preferably a LAMP-2B protein.

[0044] In some embodiments, the therapeutically effective dose is approximately 2 × 10⁻¹⁶ per kilogram (kg) of the subject's body weight.14 It is less than the vector genome (vg).

[0045] In some embodiments, the therapeutically effective amount is about 1.5×10 14 less than vg / kg.

[0046] In another aspect, the present disclosure provides a kit comprising a unit dose, pharmaceutical composition, or composition for use of the present disclosure and instructions for use in the treatment of Danon disease.

[0047] The kit may further comprise one or more unit doses, pharmaceutical compositions, or compositions comprising one or more of rituximab, tacrolimus, eculizumab, and corticosteroids.

[0048] Further aspects and embodiments of the present invention are disclosed in the form for carrying out the following invention.

Brief Description of the Drawings

[0049] [Figure 1] Shows a diagram of the pAAV-LAMP2B transfer plasmid used to generate adeno-associated virus (AAV) particles in the present disclosure. The AAV particles include an expression cassette adjacent to the inverted terminal repeat (ITR) element derived from AAV2, and the cytomegalovirus (CMV) immediate early enhancer, chicken beta-actin (CBA) promoter, chicken beta-actin, and rabbit globin intron (CBA / RbG intron) composed of the CAG promoter, the LAMP2B transgene, the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), and the rabbit globin polyadenylation signal (RGpA). [Figure 2]Figures 2A-2B show graphs of cardiac tissue analysis in WT or LAMP2 KO mice injected with PBS or various doses of AAV9.LAMP2B (1 × 10¹³, 5 × 10¹³, and 1 × 10¹⁴ vg / kg). Figure 2A shows the vector copy number per nucleus (VCN / nucleus) determined using qPCR. Figure 2B shows quantitative RT-PCR of LAMP2B mRNA levels (magnitude change compared to PBS, normalized by GAPDH). Primers detect both human and mouse LAMP2B mRNA. Values ​​are mean ± standard error. For PBS-injected KO mice, ## is p<0.01 and ### is p<0.0001. [Figure 3A] Figures 3A-3C show graphs of human LAMP2 and LC3-II protein expression in cardiac tissue. Figure 3A shows protein lysates from the hearts of Lamp2 KO mice injected with PBS or increasing doses of AAV9.LAMP2B (1 × 10¹³, 5 × 10¹³, and 1 × 10¹⁴ vg / kg), as well as from mice used as loading controls (mLAMP2) and untreated control WT mice evaluated by Western blotting against human LAMP2 (hLAMP2), LC3-II (autophagy marker), and GAPDH. Figure 3B shows the quantification of hLAMP2 protein normalized to GAPDH (densitometry using ImageJ). Figure 3C shows the quantification of LC3-II normalized to GAPDH (densitometry using ImageJ). Values ​​are mean ± standard error. For WT mice, ** showed p<0.01, and for PBS-injected KO mice, # showed p<0.05 and ## showed p<0.01. [Figure 3B] Please refer to the explanation in Figure 3A. [Figure 3C] Please refer to the explanation in Figure 3A. [Figure 4] The images show transmission electron microscope images of cardiac tissue exhibiting vacuoles (autophagy structures indicated by yellow arrows). These are representative images from WT or Lamp2 KO mice injected with PBS or 5 × 10¹³ or 1 × 10¹⁴ vg / kg of AAV9.LAMP2B. The scale bars represent 2 μm in the upper panel and 0.54 μm in the lower panel. [Figure 5] This graph shows vector DNA copies per diploid genome in patients treated with 6.7 × 10¹³ GC / kg of AAV9.LAMP2B. Patients 1001, 1002, and 1005 were analyzed at baseline, 8 weeks, 6 months, and 12 months post-treatment. [Figure 6] The images show immunohistochemical images of cardiac tissue from patient 1002 exhibiting cardiac LAMP2B expression. Representative images are from patients treated with 6.7 × 10¹³ GC / kg of AAV9.LAMP2B before administration, as a positive control, or at 8 weeks, 6 months, and 12 months post-treatment. Scale bar is 100 μm. [Figure 7] Figures 7A–7C show graphs of the change in brain natriuretic peptide (BNP) levels compared to baseline for patient 1001 (Figure 7A), patient 1002 (Figure 7B), and patient 1005 (Figure 7C). Patients were treated with 6.7 × 10¹³ GC / kg of AAV9.LAMP2B, and the change in BNP levels was analyzed at 8 weeks, 6 months, and 12 months post-treatment. [Figure 8] This diagram shows the enrollment order of the research cohort in a scenario where DLTs are not identified. [Figure 9] This diagram shows the enrollment sequence for any given cohort under the condition of a single DLT within that cohort. Enrollment within the cohort is stopped when a second patient experiences a DLT. A triangle / exclamation mark indicates the occurrence of DLT in patient 2. [Figure 10A]Figures 10A-10D are charts showing the AAV9.LAMP2B study evaluation and treatment event table. Abbreviations: AAV9: Adeno-associated virus serotype 9, ADA: Antidrug antibody, aPTT: Activated partial thromboplastin time, BNP: Brain natriuretic peptide, C3: Complement 3, C4: Complement 4, CBC: Complete blood count, CK-MB: Creatinine kinase-MB, D: Day, d / c: Discontinuation, ECG: Electrocardiogram, HBV: Hepatitis B virus, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, IgG: Immunoglobulin G, IgM: Immunoglobulin M, IP: Investigational drug, IV: Intravenous infusion, LFT: Liver function test, M: Month, MRI: Magnetic resonance imaging, PMBC: Peripheral blood mononuclear cells, PRO: Patient-reported outcome, PT: Prothrombin time, QOL: Quality of life, sC5b-9: Serum membrane invasion complex, TAT: Thrombin-antithrombin complex, VO2: Maximum oxygen consumption, W: Week. [Figure 10B] Please refer to the explanation in Figure 10A. [Figure 10C] Please refer to the explanation in Figure 10A. [Figure 10D] Please refer to the explanation in Figure 10A. [Figure 11] Figures 11A and 11B show graphs of cardiac contractility (Figure 11A) and cardiac relaxation (Figure 11B) analyzed by invasive left ventricular pressure (maximum dP / dt and minimum dP / dt, respectively) in Lamp2 KO mice or untreated control WT mice injected with PBS or increasing doses of AAV9.LAMP2B (1 × 10¹³, 5 × 10¹³, and 1 × 10¹⁴ vg / kg). [Figure 12] The images show transmission electron microscope images of cardiac tissue exhibiting vacuoles (autophagy structures indicated by yellow arrows). These are representative images from WT or Lamp2 KO mice injected with PBS or AAV9.LAMP2B at concentrations of 5 × 10¹³, 1 × 10¹⁴ vg / kg, or 2 × 10¹⁴ vg / kg. The scale bars represent 2 μm in the upper panel and 0.6 μm in the lower panel. [Figure 13]Figures 13A and 13B show graphs of cardiac contractility (Figure 13A) and cardiac relaxation (Figure 13B) analyzed by invasive left ventricular hemodynamics (maximum dP / dt and minimum dP / dt, respectively) in Lamp2 KO mice or untreated control WT mice injected with PBS or increasing doses of AAV9.LAMP2B (1 × 10¹³, 5 × 10¹³, 1 × 10¹⁴, and 2 × 10¹⁴ vg / kg). [Figure 14A] Figures 14A and 14B show LAMP2 protein expression by immunohistochemistry (Figure 14A) and cell morphology by electron microscopy (Figure 14B) after treatment with low-dose RP-A501. Representative images from patient 1005 from a ventricular septal biopsy are shown. [Figure 14B] Please refer to the explanation in Figure 14A. [Figure 15A] This study illustrates echocardiographic remodeling of ventricular hypertrophy with decreased or stabilized wall thickness in both low-dose and high-dose patients. All echocardiographic parameters are based on on-site clinical laboratory assessments performed with a single reader. [Figure 15B] This shows stabilization or improvement of left ventricular (LV) ejection fraction (EF) and wall thickness in both low-dose and high-dose patients. All echocardiographic parameters are based on on-site clinical laboratory assessments performed with a single reader. [Figure 15C] This indicates that invasive hemodynamics showed long-term stabilization or improvement of diastolic dysfunction (LV filling pressure) as measured by pulmonary capillary wedge pressure in both low-dose and high-dose patients. [Figure 15D] This demonstrates hemodynamic stabilization or improvement of systolic function in both high-dose and low-dose patients. [Modes for carrying out the invention]

[0050] Detailed description of the invention This disclosure provides methods and compositions for the treatment of Danon disease in human subjects. The inventors have demonstrated successful treatment of Danon disease in human subjects using an adeno-associated virus (AAV) designed to express the LAMP-2B isoform of LAMP-2. This AAV may be administered in combination with treatment with corticosteroids, tacrolimus, rituximab, and / or eculizumab, and the AAV may be administered in various doses. As disclosed herein, approximately 6.7 × 10⁻⁶ 13 ≤vg / kg ~ approximately 2.0 × 10 14 Doses in the range of vg / kg or higher may be safe and effective in treating Danon disease.

[0051] Vector array The wild-type polypeptide sequence of human LAMP-2B (SEQ ID NO: 1) and the wild-type polynucleotide sequence encoding human LAMP-2B (SEQ ID NO: 2) are, respectively, TIFF2023552443000002.tif27146 (SEQ ID NO: 1) and This is TIFF2023552443000003.tif83148 (sequence number 2).

[0052] Modified polynucleotide sequences encoding isoforms of lysosome-associated membrane protein 2 (LAMP-2) or functional variants thereof are disclosed herein. In certain embodiments, the modified polynucleotide sequence includes one or more of the following compared to the wild-type polynucleotide encoding a LAMP-2 isoform: codon optimization, CpG depletion, removal of hidden splice sites, or a reduced number of alternative open reading frames (ORFs). In some embodiments, the modified polynucleotide encodes a functional variant of LAMP-2A, LAMP-2B, LAMP-2C, or any of their isoforms. In embodiments, the disclosure provides polynucleotide sequences or transgenes encoding LAMP-2B or a functional variant thereof, comprising one or more nucleotide substitutions compared to SEQ ID NO: 2. In embodiments, the transgene shares at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete identity with a sequence selected from SEQ ID NOs. This disclosure includes at least three exemplary variant transgene sequences encoding LAMP-2B (SEQ ID NOs. 3-5): TIFF2023552443000004.tif83148 (Sequence ID 3), TIFF2023552443000005.tif83148 (SEQ ID NO: 4), and Provides TIFF2023552443000006.tif83148 (Sequence ID 5).

[0053] In one embodiment, the introduced gene shares at least 95% identity with a sequence selected from sequence numbers 2-5. In one embodiment, the introduced gene shares at least 99% identity with a sequence selected from sequence numbers 2-5. In one embodiment, the introduced gene contains a sequence selected from sequence numbers 2-5. In one embodiment, the introduced gene shares at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete identity with sequence number 3. In one embodiment, the introduced gene shares at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete identity with sequence number 4. In one embodiment, the introduced gene shares at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete identity with SEQ ID NO: 5.

[0054] In some embodiments, the transgene is similar to or identical to any one of the subsequences of SEQ ID NOs. 2-5. In some embodiments, the transgene contains any one of the subsequences of SEQ ID NOs. 5. In various embodiments, the subsequence may contain any sequence of consecutive nucleotides (nt) in a complete sequence having a length of at least about 50 nucleotides (nt), at least about 100 nt, at least about 150 nt, at least about 250 nt, at least about 200 nt, at least about 350 nt, at least about 450 nt, at least about 400 nt, at least about 450 nt, at least about 550 nt, at least about 600 nt, at least about 650 nt, at least about 600 nt, at least about 650 nt, at least about 700 nt, at least about 750 nt, at least about 800 nt, at least about 850 nt, at least about 900 nt, at least about 950 nt, or at least about 1000 nt.

[0055] In some embodiments, the transgene shares at least 95% identity with a subsequence containing nucleotides 1-500, 250-750, 500-1000, or 750-1240 of any one of SEQ ID NOs. 3-5. In one embodiment, the transgene shares at least 99% identity with a subsequence containing nucleotides 1-500, 250-750, 500-1000, or 750-1240 of any one of SEQ ID NOs. 5. In one embodiment, the transgene contains a sequence containing nucleotides 1-500, 250-750, 500-1000, or 750-1240 of any one of SEQ ID NOs. 2-5. In one embodiment, the transgene shares at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete identity with respect to a subsequence containing nucleotides 1-500, 250-750, 500-1000, or 750-1240 of any one of sequence numbers 2-5. In another embodiment, the transgene shares at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete identity with respect to a subsequence containing nucleotides 1-500, 250-750, 500-1000, or 750-1240 of sequence number 3. In the embodiment, the transgene shares at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete identity with respect to a subsequence of nucleotides 1-500, 250-750, 500-1000, or 750-1240 of SEQ ID NO: 3.

[0056] In certain embodiments, the transgene encodes any of the various isoforms of LAMP-2, including LAMP-2A, LAMP-2B, or LAMP-2C, or any functional fragment or variant thereof. Accordingly, in certain embodiments, the expression cassette is an optimized polynucleotide sequence encoding any of the LAMP-2A, LAMP-2B, or LAMP-2C, or any functional fragment or variant thereof, comprising one or more modifications compared to the corresponding wild-type polynucleotide sequence, selected from: codon optimization of the transgene sequence encoding LAMP-2A, LAMP-2B, or LAMP-2C; the expression cassette or transgene sequence containing fewer CpG sites than the corresponding wild-type sequence; the expression cassette or transgene sequence containing fewer hidden splice sites than the corresponding wild-type sequence; and / or the expression cassette or transgene sequence containing fewer open reading frames than the corresponding wild-type sequence. In certain embodiments, the optimized sequence is optimized for increased expression in human cells. The wild-type human polynucleotide sequences encoding the LAMP-2A and LAMP-2C isoforms are described in SEQ ID NO: 29 and SEQ ID NO: 30, respectively. The wild-type sequences of the human LAMP-2A and human LAMP-2C proteins are described in SEQ ID NO: 34 and SEQ ID NO: 35, respectively. The sequences and coding sequences of the wild-type LAMP-2 isoforms are also publicly available. While specific embodiments relating to LAMP-2B are described herein, it is understood that LAMP-2A or LAMP-2C may be used instead in each embodiment.

[0057] The coding sequences for wild-type LAMP-2A (SEQ ID NO: 29) and wild-type LAMP-2C (SEQ ID NO: 30) are 100% identical to the coding sequence for wild-type LAMP-2B (SEQ ID NO: 2) over at least nucleotides 1-1080. Therefore, those skilled in the art will readily recognize that the transgenes, expression cassettes, and vectors disclosed herein can be adapted for the expression of these isoforms of LAMP-2 by substituting nucleotides 1081-1233 of LAMP-2B (e.g., any optimized LAMP-2B from SEQ ID NOs. 3-5) for nucleotides 1081-1233 of either LAMP-2A (SEQ ID NO: 29) or wild-type LAMP-2C (SEQ ID NO: 30) at the 3′ end (nucleotides 1081-30). For example, embodiments of the present invention utilize the optimized LAMP-2B gene sequences, SEQ ID NOs. 31-33, and nucleotides 1-1080 of SEQ ID NOs. 3-5, respectively.

[0058] In one embodiment, the transgene shares at least 95% identity with a sequence selected from sequence numbers 31-33. In one embodiment, the transgene shares at least 99% identity with a sequence selected from sequence numbers 31-33. In one embodiment, the transgene contains a sequence selected from sequence numbers 31-33. In one embodiment, the transgene shares at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete identity with sequence number 31. In one embodiment, the transgene shares at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete identity with sequence number 32. In one embodiment, the transgene shares at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or complete identity with respect to SEQ ID NO: 33. In some cases, the transgene has a polynucleotide sequence that is different from the polynucleotide sequence of the reference sequence, e.g., the "natural" or "wild" LAMP-2B sequence. In some embodiments, the transgene shares up to 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95% identity with respect to the reference sequence. In some embodiments, the reference sequence is SEQ ID NO: 2. For example, sequence number 3 shares 78.5% identity with sequence number 2.

[0059] In some cases, the transgene has a polynucleotide sequence that differs from the polynucleotide sequence of the reference sequence, e.g., the “natural” or “wild-type” LAMP-2A sequence. In some embodiments, the transgene shares up to 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95% identity with respect to the reference sequence. In some embodiments, the reference sequence is the wild-type human LAMP-2A sequence described in Sequence ID No. 29.

[0060] In some cases, the transgene has a polynucleotide sequence that differs from the polynucleotide sequence of the reference sequence, e.g., the “natural” or “wild-type” LAMP-2C sequence. In some embodiments, the transgene shares up to 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95% identity with respect to the reference sequence. In some embodiments, the reference sequence is the wild-type human LAMP-2C sequence described in Sequence ID No. 30.

[0061] In one embodiment, the transgene is codon-optimized for expression in human host cells. In one embodiment, the transgene coding sequence is modified, or “codon-optimized,” to enhance expression by replacing rarely presented codons with more frequently presented codons. This coding sequence is the portion of the mRNA sequence that codes for amino acids for translation. During translation, each of the 61 trinucleotide codons is translated to one of 20 amino acids, resulting in degenerate or redundant genetic coding. However, different cell types and different animal species utilize tRNAs (each with an anticodon) that code for the same amino acid at different frequencies. If the gene sequence contains codons that are rarely presented by the corresponding tRNA, the ribosome translation mechanism may slow down, hindering efficient translation. For specific species, expression can be improved through "codon optimization," where the coding sequence is modified to encode the same protein sequence, but using codons that are highly presented and / or utilized by highly expressed human proteins (Cid-Arregui et al., 2003; J.Virol. 77:4928).

[0062] In some embodiments, the coding sequence of the transgene is modified to replace codons that are rarely expressed in mammals or primates with codons that are frequently expressed in primates. For example, in some embodiments, the transgene codes for a polypeptide having at least 85% sequence identity to a reference polypeptide (e.g., wild-type LAMP-2B, SEQ ID NO: 3), for example, at least 90% sequence identity, at least 95% sequence identity, at least 98% identity, or at least 99% identity to the reference polypeptide, where at least one codon of the coding sequence has a higher tRNA frequency in humans than the corresponding codon in the sequences disclosed above or herein.

[0063] In one embodiment, the transgene contains fewer alternative open reading frames than SEQ ID NO: 2. In one embodiment, the transgene is modified to enhance expression by terminating or removing open reading frames (ORFs) that do not encode the desired transgene. An open reading frame (ORF) is a nucleic acid sequence that follows a start codon but does not contain a stop codon. The ORF may be forward or reversed, and may be "in-frame" or "out-of-frame" relative to the gene of interest. Such open reading frames may be expressed in the expression cassette along with the gene of interest and may cause undesirable adverse effects. In some embodiments, the transgene is modified to remove open reading frames by further altering codon usage. This may be done by removing one or more start codons (ATGs) and / or by introducing one or more stop codons (TAG, TAA, or TGA) in the reverse direction or out-of-frame relative to the desired ORF, while preserving the amino acid sequence encoded by the gene of interest and maintaining selectively highly utilized codons (i.e., avoiding codons with a frequency of less than 20%).

[0064] In some embodiments, the expression cassette contains up to one, two, three, four, or five start codons 5′ to the start codon of the transgene. In some embodiments, the expression cassette does not contain a start codon 5′ to the start codon of the transgene. In some embodiments, one or more ATG codons in the 5′ UTR, promoter, enhance, promoter / enhancer element, or other sequence 5′ to the start codon of the transgene remain after one or more hidden start sites are removed. In some embodiments, the expression cassette does not contain a hidden start site upstream of the transgene to avoid generating false mRNA.

[0065] In modifications of this disclosure, the transgene coding sequence may be optimized using either codon optimization, removal of non-transgene ORFs, or both techniques. In some cases, non-transgene ORFs are removed or minimized after codon optimization in order to remove ORFs introduced during codon optimization.

[0066] In one embodiment, the transgene contains fewer CpG sites than SEQ ID NO: 2. While not theoretically bound, the presence of CpG sites in a polynucleotide sequence is thought to be associated with an undesirable host immune response to a viral vector containing that polynucleotide sequence. In some embodiments, the transgene is designed to reduce the number of CpG sites. An exemplary method is provided in U.S. Patent Application Publication 2002 / 0065236A1.

[0067] In one embodiment, the transgene contains fewer hidden splice sites than SEQ ID NO: 2. For optimization, GeneArt® software can be used to increase the GC content and / or remove hidden splice sites to avoid transcriptional silencing, for example, and thus increase the expression of the transgene. Alternatively, any optimization method known in the art may be used. Removal of hidden splice sites is described, for example, in International Patent Application Publication No. 2004 / 015106A1.

[0068] Expression cassettes and gene therapy vectors encoding LAMP-2B are also disclosed herein. In certain embodiments, the expression cassettes and gene therapy vectors include codon-optimized or variant LAMP-2B polynucleotide sequences or transgene sequences disclosed herein.

[0069] In certain embodiments, expression cassettes and gene therapy vectors encoding LAMP-2B include a consensus-optimized Kozak sequence and a full-length polyadenylated (poly-A) sequence (or substitution of full-length poly-A with cleaved poly-A), and include or do not include a minimal upstream (i.e., 5′ side) or hidden start codon (i.e., ATG site). In some embodiments, the expression cassette does not include an start site on the 5′ side of the transgene that can generate alternative mRNA. In certain embodiments, the expression cassette or gene therapy vector includes a sequence encoding LAMP-2B, e.g., a codon-optimized or variant LAMP-2B polynucleotide sequence or transgene sequence disclosed herein.

[0070] In some embodiments, the expression cassette includes two or more of the following: a first inverted terminal repeat sequence, an enhancer / promoter region, a consensus optimal Kozak sequence, a transgene (e.g., a transgene encoding LAMP-2B as disclosed herein), a 3′ untranslated region containing a full-length polyA sequence, and a second inverted terminal repeat sequence. In some embodiments, one or both of the inverted terminal repeat sequences (ITRs) are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, or AAV9 ITRs, or any one ITR known in the art. In some embodiments, the expression cassette includes exactly two ITRs. In some embodiments, both ITRs are AAV2, AAV5, or AAV9 ITRs. In some embodiments, both ITRs are AAV2 ITRs.

[0071] In one embodiment, the expression cassette includes a Kozak sequence operably linked to the transgene. In one embodiment, the Kozak sequence is sequence number 6: GCCGCCACCATGG (Sequence ID 6) It is a consensus-optimal Kosak sequence that includes or consists of the following.

[0072] In various embodiments, the expression cassette includes alternative Kozak sequences operably linked to the transgene. In one embodiment, the Kozak sequences are sequence numbers 14-18: (gcc)gccRccAUGG(sequence number 14), AGNNAUGN (Sequence ID 15), ANNAUGG (Sequence ID 16), ACCAUGG (SEQ ID NO: 17), GACACCAUGG (Sequence ID 18) It is an alternative Kossack sequence that contains or consists of one of the following.

[0073] In some embodiments, the expression cassette includes a Kozak sequence.

[0074] In sequence number 14, lowercase letters indicate the most common base at a position where the base can still change, uppercase letters indicate a highly conserved base, and R indicates adenine or guanine. In sequence number 14, the sequence in parentheses (GCC) is optional. In sequence numbers 15-17, "N" indicates any base.

[0075] Various sequences can be used as translation initiation sites instead of this consensus-optimized Kozak sequence, and identifying and testing other sequences is within the scope of the skills of those skilled in the art. See Kozak M. An analysis of vertebrate mRNA sequences: intimations of translational control. J. Cell Biol. 115(4):887-903 (1991).

[0076] In one embodiment, the expression cassette includes a full-length polyA sequence operably linked to the transgene. In one embodiment, the full-length polyA sequence is sequence number 7: Includes TIFF2023552443000007.tif27146 (sequence number 7).

[0077] Various alternative polyA sequences, including but not limited to the bovine growth hormone polyadenylation signal (bGHpA) (SEQ ID NO: 19), the SV40 early / late polyadenylation signal (SEQ ID NO: 20), and the human growth hormone (HGH) polyadenylation signal (SEQ ID NO: 21), may be used in the expression cassette of this disclosure: TIFF2023552443000008.tif15146 (Sequence ID 19), TIFF2023552443000009.tif15146 (Sequence ID 20), TIFF2023552443000010.tif15146 (Sequence ID 21).

[0078] In some embodiments, the expression cassette includes an active fragment of a polyA sequence. In certain embodiments, the active fragment of a polyA sequence includes, for example, less than 20 base pairs (bp), less than 50 bp, less than 100 bp, or less than 150 bp of any of the polyA sequences disclosed herein.

[0079] In some cases, transgene expression is increased by ensuring that the expression cassette does not contain any competing ORFs. In one embodiment, the expression cassette does not contain a start codon within 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, or 500 base pairs 5′ of the transgene's start codon. In some embodiments, the expression cassette does not contain a start codon 5′ of the transgene's start codon. In some embodiments, the expression cassette does not contain an start site 5′ of the transgene that can generate alternative mRNA.

[0080] In one embodiment, the expression cassette comprises a first inverted-terminal repeat sequence operably linked in the 5′ to 3′ direction, an enhancer / promoter region, an intron, a consensus-optimal Koszak sequence, a transgene, a 3′ untranslated region containing a full-length polyA sequence, and a second inverted-terminal repeat sequence, wherein the expression cassette does not contain a start codon on the 5′ side of the transgene that can generate alternative mRNA.

[0081] In some embodiments, the enhancer / promoter region includes a CMV IE enhancer and a chicken beta-actin promoter in the 5′ to 3′ direction. In one embodiment, the enhancer / promoter region includes a CAG promoter (SEQ ID NO: 22). As used herein, “CAG promoter” refers to a polynucleotide sequence comprising a CMV early enhancer element, a chicken beta-actin promoter, the first exon and first intron of the chicken beta-actin gene, and a splice acceptor derived from the rabbit beta-globin gene. TIFF2023552443000011.tif115148 (Sequence ID 22).

[0082] In some embodiments, the enhancer / promoter region includes a ubiquitous promoter. In some embodiments, the enhancer / promoter region includes a CMV promoter (SEQ ID NO: 23), an SV40 promoter (SEQ ID NO: 24), a PGK promoter (SEQ ID NO: 25), and / or a human beta-actin promoter (SEQ ID NO: 26). In some embodiments, the enhancer / promoter region includes a polynucleotide that shares at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NOs: 23-26. TIFF2023552443000012.tif15146 (Sequence ID 23), TIFF2023552443000013.tif23146 (Sequence ID 24), TIFF2023552443000014.tif35146 (Sequence ID 25), TIFF2023552443000015.tif162148 (Sequence ID 26).

[0083] Further exemplary promoters include, but are not limited to, the human elongation factor 1 alpha promoter (EFS), the SV40 early promoter, the mouse mammary tumor virus long inverted terminal repeat (LTR) promoter, the adenovirus major late promoter (Ad MLP), the herpes simplex virus (HSV) promoter, heterologous endogenous cell promoters for the target gene, the cytomegalovirus (CMV) promoter, such as the CMV very early promoter region (CMVIE), the Rous sarcoma virus (RSV) promoter, synthetic promoters, and hybrid promoters.

[0084] In some embodiments, the 3′UTR includes a polynucleotide (WPRE element) that shares at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with respect to SEQ ID NO: 27. TIFF2023552443000016.tif39146 (Sequence ID 27).

[0085] In some embodiments, the expression cassette shares at least 95% identity with a sequence selected from sequence numbers 8-10. In one embodiment, the expression cassette shares complete identity with a sequence selected from sequence numbers 8-10, or shares at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with a sequence selected from sequence numbers 8-10: TIFF2023552443000017.tif179148TIFF2023552443000018.tif123148 ​​(Sequence ID 8), TIFF2023552443000019.tif103148TIFF2023552443000020.tif199148 (SEQ ID NO: 9), and TIFF2023552443000021.tif23146 TIFF2023552443000022.tif242148 TIFF2023552443000023.tif35148 (Sequence ID 10).

[0086] In certain embodiments, the expression cassette includes one or more modifications, including but not limited to any of the modifications disclosed herein, compared to a sequence selected from SEQ ID NOs: 8-10. In certain embodiments, one or more modifications include one or more of the following: removal of one or more (e.g., all) upstream ATG sequences; substitution of a Kozak sequence with an optimized consensus Kozak sequence or another Kozak sequence (including but not limited to any of those disclosed herein); and / or substitution of a polyadenylated sequence with a full-length polyadenylated sequence or another polyadenylated sequence (including but not limited to any of those disclosed herein). Illustrative configurations of genetic elements within these exemplary expression cassettes are shown in Figure 1.

[0087] In one embodiment, the vector is an adeno-associated virus (AAV) vector. In one embodiment, the expression cassette includes an inverted terminal repeat (ITR) selected from SEQ ID NOs: 11 and 12: TIFF2023552443000024.tif11146 (Sequence ID 11), TIFF2023552443000025.tif11146 (Sequence ID 12).

[0088] In related embodiments, this disclosure provides gene therapy vectors comprising an expression cassette disclosed herein. Generally, the gene therapy vectors described herein comprise an expression cassette comprising a polynucleotide encoding one or more isoforms of lysosome-associated membrane protein 2 (LAMP-2), enabling the expression of LAMP-2 to partially or completely regulate insufficient LAMP-2 protein expression levels and / or autophagy flux in subjects in need thereof (e.g., subjects with Danon disease or other disorders characterized by insufficient autophagy flux at least partially attributable to insufficient LAMP-2 expression). In certain embodiments, the expression cassette comprises a polynucleotide sequence encoding LAMP-2 disclosed herein, e.g., SEQ ID NOs. 2-5, or a functional variant thereof. In some embodiments, the variant sequence has at least 90%, at least 95%, at least 98%, or at least 99% identity to any of SEQ ID NOs. 2-5. In some embodiments, the variant is a fragment of any of sequence numbers 2 to 5, for example, a fragment having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of any of sequence numbers 2 to 5.

[0089] Gene therapy vectors Gene therapy vectors can be viral or non-viral vectors. Illustrative non-viral vectors include, for example, naked DNA, cationic liposome complexes, cationic polymer complexes, cationic liposome-polymer complexes, and exosomes. Examples of viral vectors include, but are not limited to, adenovirus vectors, retrovirus vectors, lentivirus vectors, herpesvirus vectors, and adeno-associated virus (AAV) vectors.

[0090] In the compositions and methods described herein, the viral vector is generally an AAV vector. AAV is a 4.7 kb single-stranded DNA virus. Because wild-type AAV is nonpathogenic and uncaused by any known disease, recombinant vectors based on AAV are associated with excellent clinical safety. In addition, AAV offers highly efficient gene delivery and sustained transgene expression capabilities in a wide range of tissues. "AAV vector" means a vector derived from adeno-associated virus serotypes, including but not limited to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAVrh.10, AAVrh.74, etc. An AAV vector may have one or more AAV wild-type genes that are whole or partially deleted, e.g., the rep gene and / or the cap gene, but may retain adjacent functional inverted terminal repeats (ITRs). Functional ITR sequences are required for the rescue, replication, and packaging of AAV virions. Therefore, AAV vectors are defined herein to include at least the sequences required in cis for viral replication and packaging (e.g., functional ITRs). ITRs do not need to be wild-type nucleotide sequences and may be modified, for example, by nucleotide insertions, deletions, or substitutions, as long as those sequences provide functional rescue, replication, and packaging. AAV vectors include, but are not limited to, one or more modified capsid proteins (e.g., VP1, VP2, and / or VP3). For example, capsid proteins may be modified to alter their directivity and / or reduce their immunogenicity.

[0091] Immunogenicity against AAV is expected. The expression of antibodies against the viral capsid and / or transgene after administration of AAV therapy has been reported in the literature (Mendell et al. New Engl. J. Med. 377:1713-1722 (2017), Rangarajan et al. New Engl. J. Med. 377:2519-2530 (2017)). Consistent with the published literature, the study conducted in this disclosure similarly showed an increase in serum neutralizing antibodies against AAV9 at 30 and 91 days post-administration. Although vector delivery induced a characteristic binding antibody response to the AAV9 capsid, no significant anti-drug antibody (ADA) response against LAMP2B was observed, and no detectable results regarding transduction-mediated LAMP2B function in target tissue were obtained.

[0092] Because wild-type AAV is non-pathogenic and uncaused by any known disease, recombinant vectors based on AAV are associated with excellent clinical safety. In addition, AAV offers highly efficient gene delivery and sustained transgene expression capabilities in a wide range of tissues. Various serotypes of AAV are known, including AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAVrh.10, and AAVrh.74. AAV vectors may contain one or more of the AAV wild-type genes, either entirely or partially deleted, such as the rep gene and / or cap gene, but may retain adjacent functional inverted terminal repeats (ITRs). The serotype of a recombinant AAV vector is determined by its capsid. International Patent Publication 2003 / 042397A2 discloses various capsid sequences, including those of AAV1, AAV2, AAV3, AAV8, AAV9, and rh10. International Patent Publication 2013 / 078316A1 discloses the polypeptide sequence of VP1 derived from AAVrh74. A large number of diverse naturally occurring or genetically modified AAV capsid sequences are known in the art.

[0093] An illustrative and non-limiting capsid is an AAV9 capsid (or its VP1, VP2, or VP3 fragment) having the sequence of SEQ ID NO: 28. In some embodiments, the AAV vector of the present disclosure comprises a capsid protein that shares at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identity with the entire sequence of SEQ ID NO: 28, amino acids 138-736 of SEQ ID NO: 28, or amino acids 203-736 of SEQ ID NO: 28. TIFF2023552443000026.tif51146 (Sequence ID 28).

[0094] AAV expression vectors are constructed using known techniques to provide at least regulatory elements, including a transcription start region, the target DNA (i.e., the LAMP-2 gene), and a transcription termination region, as components operably linked in the transcription direction.

[0095] In some embodiments, the viral vector is an AAV9 vector. In some embodiments, the expression cassette of the viral vector is adjacent to an AAV2 inverted terminal repeat (ITR). ITRs used in alternative embodiments of the vectors of this disclosure include, but are not limited to, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, and AAV9. In some embodiments, the viral vector is an AAV2 / 9 vector. The notation AAV2 / 9 means that the AAV vector has an AAV2 ITR and an AAV9 capsid. Other embodiments of this disclosure include, but are not limited to, AAV2 / 9, AAV5 / 9, AAVrh74, AAV2 / rh74, AAV5 / 9, and AAV5 / rh74 vectors. Other ITRs known in the art may be used. Examples of useful ITRs (and other AAV components) for the vectors of this disclosure include, but are not limited to, those described in US6936466B2, US9169494B2, US2005 / 0220766A1, US2019 / 0022249A1, and US7282199B2, each of which is incorporated herein by reference in whole.

[0096] Gene delivery viral vectors useful for carrying out the present invention can be constructed using methodologies well known in the field of molecular biology. Typically, a transgene-carrying viral vector is constructed from polynucleotides encoding a transgene, suitable regulatory elements, and elements necessary for the production of viral proteins, which mediate cell transduction. Such recombinant viruses can be generated by techniques known in the art, for example, by transfecting or transiently transfecting packaging cells with a helper plasmid or virus. Typical examples of viral packaging cells include, but are not limited to, HeLa cells, SF9 cells (optionally carrying a baculovirus helper vector), and 293 cells. AAV vectors can be produced using herpesvirus-based systems, as described in US2017 / 0218395A1. Detailed protocols for producing such replication-deficient recombinant viruses are described, for example, in W095 / 14785, W096 / 22378, U.S. Patent No. 5,882,877, U.S. Patent No. 6,013,516, U.S. Patent No. 4,861,719, U.S. Patent No. 5,278,056, and W094 / 19478, the complete contents of which are incorporated herein by reference.

[0097] This disclosure also provides pharmaceutical compositions comprising an expression cassette or vector disclosed herein (e.g., a gene therapy vector) and one or more pharmaceutically acceptable carriers, diluents, or excipients. In certain embodiments, the pharmaceutical composition comprises an AAV vector comprising an expression cassette disclosed herein, for example, the expression cassette comprising a codon-optimized transgene encoding LAMP-2B, e.g., any of SEQ ID NOs. 3 to 5, and their variants. A pharmaceutical composition is provided for use in the prevention or treatment of a disorder characterized by insufficient autophagy flux (e.g., Danon disease), comprising an expression cassette or vector initiated herein comprising a vector comprising a therapeutically effective amount of a polynucleotide nucleic acid sequence encoding one or more isoforms of LAMP-2.

[0098] AAV vectors useful for carrying out the present invention can be packaged into AAV virions (viral particles) using a variety of systems, including adenovirus-based systems and helper-free systems. Standard methods in AAV biology include those described in Kwon and Schaffer. Pharm Res. (2008) 25(3):489-99, Wu et al. Mol.Ther. (2006) 14(3):316-27, Burger et al. Mol.Ther. (2004) 10(2):302-17, Grimm et al. Curr Gene Ther. (2003) 3(4):281-304, Deyle DR, Russell DW. Curr Opin Mol Ther. (2009) 11(4):442-447, McCarty et al. Gene Ther. (2001) 8(16):1248-54, and Duan et al. Mol Ther. (2001) 4(4):383-91. Systems that did not include helpers included those described in US6,004,797, US7,588,772, and US7,094,604.

[0099] The pharmaceutical composition comprising an expression cassette or vector may be in any form suitable for a selected mode of administration, such as intraventricular, intramyocardial, intracoronary, intravenous, intraarterial, intrarenal, intraurethral, ​​epidural, or intramuscular administration. Gene therapy vectors comprising polynucleotides encoding one or more LAMP-2 isoforms can be administered to animals and humans in unit dose forms, either as a sole activator or in combination with other activators, as a mixture with a conventional pharmaceutical support. In some embodiments, the pharmaceutical composition comprises cells transduced ex vivo to any of the gene therapy vectors of this disclosure.

[0100] Treatment of Danon disease Exemplary methods for treating lysosomal disorders and / or Danon disease are provided in WO2018 / 170239A1, which are incorporated herein by reference in their entirety.

[0101] In another aspect, the Disclosure provides a method for preventing, mitigating, improving, reducing, suppressing, eliminating, and / or reversing one or more symptoms of Danon disease or another autophagy disorder in subjects requiring prevention, mitigation, improvement, reduction, suppression, and / or reversal of one or more symptoms of Danon disease or another autophagy disorder, the method comprising administering the gene therapy vector of the Disclosure to a subject. The term “Danon disease” refers to X-linked dominant skeletal muscle and cardiomyopathy with multisystem clinical manifestations. Danon disease mutations result in the absence of lysosomal-associated membrane protein 2 (LAMP-2) protein expression. Key clinical features include skeletal muscle and cardiomyopathy, cardiac conduction abnormalities, cognitive impairment, and retinal disorders. Males typically become affected earlier and more severely than females.

[0102] Cardiac injection can be performed, for example, by accessing a central vein, such as the jugular vein. AAV can be delivered to the heart using a Swan-Ganz pulmonary artery catheter (PAC) or other PACs.

[0103] In one embodiment, the vector is administered via a route selected from the group consisting of parenteral, intravenous, intraarterial, intracardiac, intracoronary, intramyocardial, intrarenal, intraurethral, ​​epidural, and intramuscular. In one embodiment, the vector is administered multiple times. In one embodiment, the vector is administered by intramuscular injection. In one embodiment, the vector is administered by injection into skeletal muscle. In one embodiment, the expression cassette includes a muscle-specific promoter, optionally a muscle creatine kinase (MCK) promoter, or an MCK / SV40 hybrid promoter, as described in Takeshita et al. Muscle creatine kinase / SV40 hybrid promoter for muscle-targeted long-term transgene expression. Int J Mol Med. 2007 Feb;19(2):309-15. In one embodiment, the vector is administered by intracardiac injection.

[0104] In one embodiment, the vector, for example, the AAV vector, is administered systemically, more specifically, intravenously. Advantageously, the vector is administered in doses (vg / mL, vg / kg body weight, or vg / min / kg) less than the dose required to observe the same response when using the original LAMP-2B sequence or the wild-type LAMP-2B sequence. In certain embodiments, the vector is an AAV2 / 9 vector comprising an expression cassette containing a polynucleotide encoding LAMP-2B as disclosed herein.

[0105] In some embodiments, the Disclosure provides a method for expressing LAMP-2B in a subject, comprising systemically administering an adeno-associated virus (AAV) vector to the subject, wherein the AAV vector comprises an expression cassette containing a transgene that shares at least 95% identity with or is identical to SEQ ID NO: 2, the transgene being operably ligated to an enhancer / promoter region, and systemically administering the AAV vector to the subject results in increased LAMP-2B expression compared to LAMP-2B expression before administration of the AAV vector or in an untreated control subject. In some embodiments, the AAV virion is an AAV2 / 9 vector, which is a vector having an AAV9 capsid and an AAV2 ITR in the vector genome. In certain embodiments, the expression cassette comprises any of the elements disclosed herein. In some embodiments, systemic administration includes intravenous administration. In some embodiments, the subject exhibits symptoms of Danon disease. In some embodiments, the subject has or is at risk of Danon disease.

[0106] In some embodiments, systemic (or more specifically intravenous) administration results in the expression of LAMP-2B polynucleotide as mRNA in the form of mRNA expressed from the transgene in one or more tissues of the subject (e.g., heart, muscle, and / or liver). In some embodiments, the expression of LAMP-2B polynucleotide as mRNA is increased in the heart by at least about 1.2 times, at least about 1.3 times, at least about 1.4 times, at least about 1.5 times, at least about 1.6 times, at least about 1.7 times, at least about 1.8 times, at least about 1.9 times, at least about 2.0 times, at least about 2.2 times, at least about 2.3 times, at least about 2.4 times, at least about 2.5 times, at least about 3 times, or at least about 4 times compared to expression in untreated subjects or subjects treated with a control vector. In some embodiments, the expression of LAMP-2B polynucleotide as mRNA increases by at least 1.2 times, at least 1.3 times, at least 1.4 times, at least 1.5 times, at least 1.6 times, at least 1.7 times, at least 1.8 times, at least 1.9 times, at least 2.0 times, at least 2.2 times, at least 2.3 times, at least 2.4 times, at least 2.5 times, at least 3 times, or at least 4 times in the heart compared to the expression in untreated subjects or subjects treated with a control vector.

[0107] In some embodiments, the expression of LAMP-2B polynucleotide as mRNA is increased in muscle by at least about 1.2 times, at least about 1.3 times, at least about 1.4 times, at least about 1.5 times, at least about 1.6 times, at least about 1.7 times, at least about 1.8 times, at least about 1.9 times, at least about 2.0 times, at least about 2.2 times, at least about 2.3 times, at least about 2.4 times, at least about 2.5 times, at least about 3 times, or at least about 4 times compared to expression in untreated subjects or subjects treated with a control vector. In some embodiments, the expression of LAMP-2B polynucleotide as mRNA is increased in muscle by at least 1.2 times, at least 1.3 times, at least 1.4 times, at least 1.5 times, at least 1.6 times, at least 1.7 times, at least 1.8 times, at least 1.9 times, at least 2.0 times, at least 2.2 times, at least 2.3 times, at least 2.4 times, at least 2.5 times, at least 3 times, or at least 4 times compared to the expression in untreated subjects or subjects treated with a control vector.

[0108] In some embodiments, the LAMP-2B transgene is expressed in the heart but not in the liver of the subject. In some embodiments, the expression of LAMP-2B polynucleotide as mRNA is observed to be at least about 1.2 times, at least about 1.3 times, at least about 1.4 times, at least about 1.5 times, at least about 1.6 times, at least about 1.7 times, at least about 1.8 times, at least about 1.9 times, at least about 2.0 times, at least about 2.2 times, at least about 2.3 times, at least about 2.4 times, at least about 2.5 times, at least about 3 times, or at least about 4 times in the heart compared to the liver. In some embodiments, the expression of LAMP-2B polynucleotide as mRNA is observed to be at least 1.2 times, at least 1.3 times, at least 1.4 times, at least 1.5 times, at least 1.6 times, at least 1.7 times, at least 1.8 times, at least 1.9 times, at least 2.0 times, at least 2.2 times, at least 2.3 times, at least 2.4 times, at least 2.5 times, at least 3 times, or at least 4 times in the heart compared to the liver. In some embodiments, the expression of LAMP-2B polynucleotide as mRNA is observed to be at least 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2.0 times, 2.2 times, 2.3 times, 2.4 times, 2.5 times, 3 times, or 4 times in the heart compared to the liver.

[0109] In some embodiments, the expression of wild-type or functional LAMP-2B protein is increased in the heart by at least about 1.2 times, at least about 1.3 times, at least about 1.4 times, at least about 1.5 times, at least about 1.6 times, at least about 1.7 times, at least about 1.8 times, at least about 1.9 times, at least about 2.0 times, at least about 2.2 times, at least about 2.3 times, at least about 2.4 times, at least about 2.5 times, at least about 3 times, or at least about 4 times compared to expression in untreated subjects or subjects treated with a control vector. In some embodiments, the expression of wild-type or functional LAMP-2B protein is increased in the heart by at least 1.2 times, at least 1.3 times, at least 1.4 times, at least 1.5 times, at least 1.6 times, at least 1.7 times, at least 1.8 times, at least 1.9 times, at least 2.0 times, at least 2.2 times, at least 2.3 times, at least 2.4 times, at least 2.5 times, at least 3 times, or at least 4 times compared to the expression in untreated subjects or subjects treated with a control vector.

[0110] In some embodiments, the expression of wild-type or functional LAMP-2B protein is observed to be at least about 1.2 times, at least about 1.3 times, at least about 1.4 times, at least about 1.5 times, at least about 1.6 times, at least about 1.7 times, at least about 1.8 times, at least about 1.9 times, at least about 2.0 times, at least about 2.2 times, at least about 2.3 times, or at least about 5 times in the heart compared to the liver. In some embodiments, the expression of wild-type or functional LAMP-2B protein is observed to be at least 1.2 times, at least 1.3 times, at least 1.4 times, at least 1.5 times, at least 1.6 times, at least 1.7 times, at least 1.8 times, at least 1.9 times, at least 2.0 times, at least 2.2 times, at least 2.3 times, at least 2.4 times, at least 2.5 times, at least 3 times, or at least 4 times in the heart compared to the liver. In some embodiments, the expression of wild-type or functional LAMP-2B protein is observed to be 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2.0 times, 2.2 times, 2.3 times, 2.4 times, 2.5 times, 3 times, or 4 times higher in the heart compared to the liver.

[0111] In some embodiments, administration of a gene therapy vector results in increased expression of wild-type or functional LAMP-2B protein in the liver by up to approximately 1.1 times, up to approximately 1.2 times, up to approximately 1.3 times, up to approximately 1.4 times, up to approximately 1.5 times, up to approximately 1.6 times, up to approximately 1.7 times, up to approximately 1.8 times, up to approximately 1.9 times, or up to approximately 2 times compared to expression in the liver of an untreated subject. In some embodiments, administration of a gene therapy vector results in a 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, or 2-fold increase in the expression of wild-type or functional LAMP-2B protein in the liver compared to the expression in the liver of an untreated subject.

[0112] In one embodiment, the Disclosure provides a method for treating a disease or disorder, a disease or disorder in a subject requiring treatment of Danon disease, the disease or disorder in a subject requiring treatment of Danon disease, the method comprising contacting cells with a gene therapy vector according to the Disclosure, and administering the cells to the subject. In one embodiment, the cells are stem cells, optionally pluripotent stem cells. In one embodiment, the stem cells can differentiate into cardiac tissue. In one embodiment, the stem cells can differentiate into muscle tissue, e.g., cardiomyocytes and / or skeletal muscle tissue. In one embodiment, the stem cells are autologous. In one embodiment, the stem cells are induced pluripotent stem cells (iPSCs).

[0113] In one embodiment, the disease or disorder is autophagy disorder. In some embodiments, the autophagy disorder is selected from the group consisting of end-stage heart failure, myocardial infarction, drug toxicity, diabetes mellitus, end-stage renal failure, and aging. In one embodiment, the subject is a mammal, e.g., human. In one embodiment, the subject exhibits symptoms of Danon disease or another autophagy disorder. In one embodiment, the subject is identified as having reduced or undetectable LAMP-2 expression. In one embodiment, the subject is identified as having a mutant LAMP-2 gene.

[0114] Subjects / patients suitable for treatment using the methods described herein include, but are not limited to, individuals who are at risk of disease or disorder characterized by insufficient autophagy flux (e.g., Danon disease, as well as other known disorders including, but not limited to, systolic and diastolic heart failure, myocardial infarction, drug toxicity (e.g., anthracyclines, chloroquine, and their derivatives), diabetes mellitus, end-stage renal disease, and aging), but are asymptomatic, as well as subjects who are currently asymptomatic. Such subjects may have been identified as having a mutant LAMP-2 gene or reduced or undetectable LAMP-2 expression levels.

[0115] In some embodiments, the subject is human. In some embodiments, the patient is a child, adolescent, or adult human. In some embodiments, the patient is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 years old, or 20 years old or older. In some embodiments, the patient is 20 to 50 years old. In some embodiments, the patient is 50 to 65 years old. In some embodiments, the patient is 1 to 5 years old, 2 to 6 years old, 3 to 7 years old, 4 to 8 years old, 5 to 9 years old, 6 to 10 years old, 7 to 11 years old, 8 to 12 years old, 9 to 13 years old, 10 to 14 years old, 11 to 15 years old, 12 to 16 years old, 13 to 17 years old, 14 to 18 years old, 15 to 19 years old, or 16 to 20 years old. In some embodiments, the patient is 5-6 years old, 6-7 years old, 7-8 years old, 8-9 years old, 9-10 years old, 10-11 years old, 11-12 years old, 12-13 years old, 13-14 years old, 14-15 years old, 15-16 years old, 16-17 years old, 17-18 years old, 18-19 years old, 19-20 years old, or 20-21 years old. In certain embodiments, the patient is 15-16 years old.

[0116] In some embodiments, the patient is a human male. In some embodiments, the patient is a child, adolescent, or adult human male. In some embodiments, the patient is a male aged 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 years old, or a male aged 20 years or older. In some embodiments, the patient is a male aged 20–50 years. In some embodiments, the patient is a male aged 50–65 years. In some embodiments, the patient is a male aged 1–5 years, 2–6 years, 3–7 years, 4–8 years, 5–9 years, 6–10 years, 7–11 years, 8–12 years, 9–13 years, 10–14 years, 11–15 years, 12–16 years, 13–17 years, 14–18 years, 15–19 years, or 16–20 years. In some embodiments, the patient is a male aged 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, 11-12, 12-13, 13-14, 14-15, 15-16, 16-17, 17-18, 18-19, 19-20, or 20-21 years. In certain embodiments, the patient is 15-16 years old.

[0117] In some embodiments, the patient is a human female. In some embodiments, the patient is a child, adolescent, or adult human female. In some embodiments, the patient is a woman aged 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 years, or a woman aged 20 or older. In some embodiments, the patient is a woman aged 20 to 50 years. In some embodiments, the patient is a woman aged 50 to 65 years.

[0118] In some embodiments, the subjects exhibit symptoms of a disease or disorder characterized by insufficient autophagy flux (e.g., Danon disease, as well as other known autophagy disorders including, but not limited to, systolic and diastolic heart failure, myocardial infarction, drug toxicity, diabetes mellitus, end-stage renal disease, and aging). These symptoms may be actively present, suppressed or controlled (e.g., by medication), or in remission. The subjects may or may not have been diagnosed with the disorder by, for example, a qualified physician.

[0119] In some embodiments, a viral vector (e.g., an AAV vector), or a pharmaceutical composition containing such a vector, is effective when administered systemically. For example, the viral vectors of this disclosure are effective in some cases when administered intravenously to a subject (e.g., a primate such as a non-human primate or a human). In some embodiments, the viral vectors of this disclosure can induce LAMP-2B expression in various tissues when administered systemically (e.g., to the heart, muscle, and / or lungs). In certain embodiments, administration to a subject of an AAV9 vector containing substantially the same transgene as SEQ ID NO: 2 or the same transgene results in detectable LAMP-2B expression in cardiac tissue. In some embodiments, LAMP-2B expression is detectable in one or more or all of the left ventricle, right ventricle, left atrium, and right atrium of the subject's heart. In some embodiments, LAMP-2B expression is detectable in partial region 1 and / or partial region 2 of the left ventricle of the subject's heart.

[0120] "Detectable expression" typically refers to the expression of a transgene at least 5%, 10%, 15%, 20%, or higher compared to a control or tissue not treated with the viral vector. In some embodiments, detectable expression means an expression at least 1.5 times, at least 2 times, at least 2.5 times, at least 3 times, at least 5 times, at least 10 times, at least 20 times, at least 50 times, or at least 100 times higher than that of a control without a vector. Transgene expression can be determined as an increase in the expression of the wild-type or endogenous gene in the cell (considering the possibility that transgene expression may affect the expression of the endogenous gene). Transgene expression can also be determined by RT-PCR detection of a sequence that is present on the mRNA transcript of the transgene but not on the mRNA transcript of the endogenous gene. For example, the 3′UTR of the transcript can be used to determine the expression of a transgene independent of the expression of the endogenous gene (which may have a different 3′UTR). The expression of the polypeptide encoded by the transgene can be evaluated by Western blotting or enzyme-linked immunosorbent assay (ELISA) as described in the following examples or as described in other methods known in the art. Antibodies that cross-react with wild-type exogenous copies of the protein may be used. In some cases, antibodies specific to the exogenous protein can be identified and used to determine the expression of the transgene. Those skilled in the art can design appropriate detection methodologies considering target cells or tissues. In some cases, expression is measured quantitatively using a standard curve. The standard curve can be generated using purified LAMP-2 protein by the methods described in the examples or by methods known in the art. Alternatively, the expression of the transgene can be evaluated by quantification of the corresponding mRNA.

[0121] As used herein, the terms “vector genome” and “genome copy” are interchangeable in referring to the number of single-stranded AAV genome polynucleotides in a sample. Vector genome copies can be measured using quantitative polymerase chain reaction (qPCR) or digital droplet polymerase chain reaction (ddPCR) with recombinant AAV genome-specific primers, such as primers adjacent to the WPRE sequence of the genome. Quantification may be performed against a standard curve generated using a reference sample, such as a sample containing plasmid DNA with the target amplicon of the primer used. ddPCR and qPCR methods are well known in the art. Preclinical dose units are expressed in vector genomes per kg of body weight (vg). Clinical doses are expressed in vector genome copies per kg of body weight (GC). Both unit terms (GC / kg and vg / kg) are intended to describe the same entity and are used interchangeably in this disclosure.

[0122] In some embodiments, detectable expression of LAMP-2B in cardiac tissue is 5 × 10¹⁶ vector genomes (vg) per kilogram (kg) of body weight of the subject. 14 vg / kg or less, 3×10 14 vg / kg or less, 2×10 14 vg / kg or less, 1×10 14 vg / kg or less, 9×10 13 vg / kg or less, 8×10 13 vg / kg or less, 7×10 13 vg / kg or less, 6×10 13 vg / kg or less, 5×10 13 vg / kg or less, 4×10 13 vg / kg or less, 3×10 13 vg / kg or less, 2×10 13 ≤vg / kg, or 1 × 10⁻⁶ 13 This occurs at doses below vg / kg.

[0123] In some embodiments, detectable expression of LAMP-2B in cardiac tissue is 1 × 10¹⁶ vector genomes (vg) per kilogram (kg) of body weight of the subject. 13 vg / kg~2×1013 vg / kg, 2 × 10 13 vg / kg~3×10 13 vg / kg, 3 × 10 13 vg / kg~4×10 13 vg / kg, 4×10 13 vg / kg~5×10 13 vg / kg, 5×10 13 vg / kg~6×10 13 vg / kg, 6×10 13 vg / kg~7×10 13 vg / kg, 7×10 13 vg / kg~8×10 13 vg / kg, 8×10 13 vg / kg~9×10 13 vg / kg, 9×10 13 vg / kg~1×10 14 vg / kg, 1 × 10 14 vg / kg~2×10 14 vg / kg, 2 × 10 14 vg / kg~3×10 14 vg / kg, or 3 × 10 14 vg / kg~5×10 14 This occurs at doses of vg / kg.

[0124] In some embodiments, detectable expression of LAMP-2B in cardiac tissue is 1 × 10¹⁶ vector genomes (vg) per kilogram (kg) of body weight of the subject. 13 vg / kg~3×10 13 vg / kg, 3 × 10 13 vg / kg~5×10 13 vg / kg, 5×10 13 vg / kg~7×10 13 vg / kg, 7×10 13 vg / kg~9×10 13 vg / kg, 9×10 13 vg / kg~2×10 14 vg / kg, or 2 × 10 14 vg / kg~5×10 14 This occurs at a dose of vg / kg. In some embodiments, detectable expression of LAMP-2B in cardiac tissue is 1 × 10⁶ vector genomes (vg) per kilogram (kg) of body weight of the subject.13 vg / kg~5×10 13 vg / kg, 5×10 13 vg / kg~9×10 13 vg / kg, 9×10 13 vg / kg~5×10 14 This occurs at a dose of vg / kg. In some embodiments, detectable expression of LAMP-2B in cardiac tissue is 1 × 10⁶ vector genomes (vg) per kilogram (kg) of body weight of the subject. 13 vg / kg~9×10 13 vg / kg or 9×10 13 vg / kg~5×10 14 This occurs at doses of vg / kg.

[0125] In some embodiments, detectable expression of LAMP-2B in cardiac tissue is 1 × 10¹⁶ vector genomes (vg) per kilogram (kg) of body weight of the subject. 13 vg / kg~5×10 13 vg / kg, 5×10 13 vg / kg~1×10 14 vg / kg, or 1 × 10⁻⁶ 14 vg / kg~5×10 14 This occurs at doses of vg / kg.

[0126] In some embodiments, detectable expression of LAMP-2B in cardiac tissue is 1 × 10¹⁶ vector genomes (vg) per kilogram (kg) of body weight of the subject. 13 vg / kg~5×10 14 This occurs at a dose of vg / kg. In some embodiments, detectable expression of LAMP-2B in cardiac tissue is 1 × 10⁶ vector genomes (vg) per kilogram (kg) of body weight of the subject. 13 vg / kg~1×10 14 This occurs at doses of vg / kg.

[0127] Simultaneous administration Safety and / or efficacy may be enhanced in some cases by the co-administration of one or more secondary agents, including but not limited to immunomodulators.

[0128] In some embodiments, the method involves administering an effective dose of a corticosteroid, including but not limited to dexamethasone, methylprednisolone, or prednisone, to the target. Appropriate doses and administration regimens of corticosteroids for AAV therapy are known in the art. See Diehl et al. Cell. & Mol. Immunol. 14, 146-179 (2017).

[0129] In some embodiments, the method involves administering an effective amount of tacrolimus, cyclosporine, rapamycin, sirolimus, or a derivative thereof to the subject. In some embodiments, the method further involves administering an effective amount of corticosteroid to the subject before administering an effective amount of tacrolimus. As disclosed herein, tacrolimus may, in some cases, allow for a more rapid gradation of corticosteroid levels after administration of AAV to the subject. Tacrolimus may be administered 7 to 21 days before AAV administration, for example, 21 days, 14 days, 10 days, 7 days, 5 days, 2 days, or 1 day before, preferably 1 day before, AAV administration. Administration of tacrolimus may be continued after AAV administration. Tacrolimus may be administered for 120 days after AAV administration, for example, over 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, or 120 days, preferably over 90 days. See Tardieu et al. Hum. Gen. Ther. 25(6):506-516 (2014).

[0130] Tacrolimus may be administered in doses of 0.01 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, or 0.6 mg / kg. Tacrolimus may be administered simultaneously with mycophenolate mofetil at doses of 700 mg / m2, 800 mg / m2, 900 mg / m2, 1000 mg / m2, 1100 mg / m2, 1200 mg / m2, 1300 mg / m2, 1400 mg / m2, 1500 mg / m2, 1600 mg / m2, or 1700 mg / m2.

[0131] In some embodiments, the method involves administering 0.2 mg / kg of tacrolimus to the subject simultaneously with 1200 mg / m2 of mycophenolate mofetil.

[0132] Tacrolimus may be administered orally once daily in two divided doses. Tacrolimus may be administered in amounts effective to maintain trough serum levels of 2 ng / mL, 2.5 ng / mL, 3 ng / mL, 3.5 ng / mL, 4 ng / mL, 4.5 ng / mL, or 5 ng / mL. Alternatives to tacrolimus include, but are not limited to, mycophenolic acid, cyclosporine, cyclosporine modifiers, sirolimus, everolimus, or beratacept.

[0133] In some embodiments, the method involves administering an effective dose of rituximab to the subject. As disclosed herein, rituximab can, in some cases, reduce and / or prevent the immune response to AAV. Rituximab may be administered 7 to 21 days prior to AAV administration, for example, 21 days, 14 days, 10 days, 7 days, 5 days, 2 days, or 1 day prior, preferably 1 day prior. Rituximab may also be administered 7 to 21 days after AAV administration, for example, 21 days, 14 days, 10 days, 7 days, 5 days, 2 days, or 1 day prior, preferably 1 day prior. Rituximab may be administered to the subject one, two, three, or more times. See Corti et al. Hum. Gene Ther. Clin. Dev. 28(4):208-218 (2017) and Corti et al. Mol. Ther. Meth. Clin. Dev. 1, 14033 (2014).

[0134] Rituximab may be administered in doses of 300 mg / m2, 400 mg / m2, 500 mg / m2, 600 mg / m2, 700 mg / m2, 750 mg / m2, 800 mg / m2, 900 mg / m2, 1000 mg / m2, 1100 mg / m2, or 1200 mg / m2, preferably 750 mg / m2. Alternatives to rituximab include, but are not limited to, obinutuzumab, ximma (rituximab-abbs), or lenalidomide.

[0135] Tacrolimus may be administered before rituximab. Tacrolimus may be administered concurrently with rituximab. Tacrolimus may be administered after rituximab. Rituximab administration may be discontinued while tacrolimus administration is ongoing.

[0136] In some embodiments, rituximab is administered 14 and 7 days before AAV administration, and tacrolimus is administered from 7 days before AAV administration until 3 months after AVV administration.

[0137] In some embodiments, the method involves administering an effective dose of eculizumab, ravulizumab, or another complement inhibitor to the target. Methods of treatment with complement inhibitors are known in the art. See Zipfel et al. Front.Immunol. (2019). Eculizumab is approved for the treatment of atypical hemolytic uremic syndrome (aHUS).

[0138] In some embodiments, subjects are at risk of developing complement activation complications such as atypical hemolytic uremic syndrome (aHUS), and optionally, reversible thrombocytopenia and / or acute kidney injury (AKI).

[0139] In some embodiments, the method further includes administering an effective dose of rituximab, administering an effective dose of tacrolimus, and / or administering an effective dose of eculizumab.

[0140] Various corticosteroids known in the art may be used. In some embodiments, the method involves administering an effective amount of dexamethasone, methylprednisolone, betamethasone, prednisone, prednisolone, triamcinolone, hydrocortisone, cortisone, fludrocortisone, or a combination thereof to the target.

[0141] Pharmaceutical composition and dosage In another embodiment, the present disclosure provides pharmaceutical compositions. In various embodiments, the pharmaceutical compositions comprise a pharmaceutically acceptable vehicle (e.g., a carrier, diluent, and excipient) for an injectable formulation. Exemplary excipients include poloxamers. Formulation buffers for viral vectors (including AAVs) comprise salts for preventing vector aggregation and other excipients (e.g., poloxamers) for reducing the stickiness of the vector. These may specifically be isotonic sterile saline solutions (such as monosodium or disodium phosphate, sodium chloride, potassium chloride, calcium chloride, or magnesium chloride, or mixtures of such salts), or optionally, dry compositions, particularly lyophilized compositions, that enable the formation of an injectable solution upon addition of sterile water or saline. Advantageously, the formulations are stable for storage and use when frozen (e.g., below 0°C, about -60°C, or about -72°C).

[0142] In some embodiments, the pharmaceutical composition comprises a buffer (e.g., phosphate buffer) at a concentration (e.g., 200 mM) and pH (e.g., pH 7.2 ± 0.1) suitable for administration to a subject. The pharmaceutical composition may also contain a suitable concentration (e.g., 0.01%) of poloxamer. The pharmaceutical composition may be provided to the treatment site as a frozen product. The final volume of the unit dose of AAV may be determined whole or partially based on the patient's body weight, e.g., kilograms (kg), and volume, e.g., per milliliter (mL), or calculated or experimentally determined levels of vector genome (vg) copies of AAV in the pharmaceutical composition. The pharmaceutical composition may be diluted as necessary to obtain a concentration or volume suitable for injection.

[0143] In some embodiments, the pharmaceutical composition contains 200 mM NaCl, 10 mM NaH2PO4, 1% (w / v) sucrose, 0.01% poloxamer 188, and pH 7.2 ± 0.1.

[0144] In some embodiments, the AAV vector is about 1×10 of the AAV vector per kilogram (vg) of the total body weight of the subject 12 ~ about 5×10 14 Vector genome (vg) (vg / kg) of the dose. In some embodiments, the AAV vector is about 1×10 13 ~ about 5×10 14 vg / kg of the dose. In some embodiments, the AAV vector is about 5×10 13 ~ about 3×10 14 vg / kg of the dose. In some embodiments, the AAV vector is about 5×10 13 ~ about 1×10 14 vg / kg of the dose. In some embodiments, the AAV vector is about 1×10 12 vg / kg less than, about 3×10 12 vg / kg less than, about 5×10 12 vg / kg less than, about 7×10 12 vg / kg less than, about 1×10 13 vg / kg less than, about 3×10 13 vg / kg less than, about 5×10 13 vg / kg less than, about 7×10 13 vg / kg less than, about 1×10 14 vg / kg less than, about 3×10 14 vg / kg less than, or about 5×10 14 vg / kg of the dose.

[0145] In some embodiments, the AAV vector is about 6.7×10 13 ~ 2×10 14 vg / kg of the dose. In some embodiments, the AAV vector is about 6.7×10 13 ~ about 1.1×10 14 vg / kg of the dose.

[0146] In some embodiments, the AAV vector is about 1×10 13 vg / kg, about 3×10 13 vg / kg, about 5×10 13 vg / kg, about 7×10 13 vg / kg, about 1×1014 vg / kg, approx. 3×10 14 vg / kg, or approximately 5 × 10 14 It is administered at a dose of vg / kg. In some embodiments, the AAV vector is approximately 6.7 × 10⁻⁶. 13 vg / kg, approximately 1.1×10 13 vg / kg, or approximately 2.0 × 10⁻⁶ 13 It is administered at a dose of vg / kg.

[0147] In some embodiments, the AAV vector is 1 × 10 12 vg / kg, 3 × 10 12 vg / kg, 5×10 12 vg / kg, 7×10 12 vg / kg, 1 × 10 13 vg / kg, 3 × 10 13 vg / kg, 5×10 13 vg / kg, 7×10 13 vg / kg, 1 × 10 14 vg / kg, 3 × 10 14 vg / kg, 5×10 14 vg / kg, 7×10 14 vg / kg, 1 × 10 15 vg / kg, 3 × 10 15 vg / kg, 5×10 15 vg / kg, or 7×10 15 It is administered at a dose of vg / kg. In some embodiments, the AAV vector is 6.7 × 10⁶ 13 vg / kg, 1.1 × 10 13 vg / kg, or 2.0 × 10 13 It is administered at a dose of vg / kg.

[0148] In some embodiments, the AAV vector is approximately 1 × 10⁶ AAV vectors per kilogram (vg) of the subject's total body weight. 13 ~5×10 14 The vector genome is administered systemically at a dose of (vg)(vg / kg). In some embodiments, the AAV vector is approximately 1 × 10⁻⁶ 13 ~5×10 14 It is administered systemically at a dose of vg / kg. In some embodiments, the AAV vector is approximately 5 × 10⁻¹⁴. 13~3×10 14 It is administered systemically at a dose of vg / kg. In some embodiments, the AAV vector is approximately 5 × 10⁻¹⁴. 13 ~1 × 10 14 It is administered systemically at a dose of vg / kg. In some embodiments, the AAV vector is approximately 1 × 10⁻⁶ 13 Less than vg / kg, approximately 3 x 10 13 Less than vg / kg, approximately 5 x 10 13 Less than vg / kg, approximately 7 x 10 13 Less than vg / kg, approximately 1 × 10⁻⁶ 14 Less than vg / kg, approximately 3 x 10 14 Less than vg / kg, or approximately 5 × 10 14 It is administered systemically at doses less than vg / kg.

[0149] In some embodiments, the AAV vector is approximately 6.7 × 10⁻⁶. 13 ~2×10 14 It is administered systemically at a dose of vg / kg. In some embodiments, the AAV vector is approximately 6.7 × 10⁻⁶. 13 ~Approx. 1.1×10 14 It is administered at a dose of vg / kg.

[0150] In some embodiments, the AAV vector is approximately 1 × 10⁻⁶ 13 vg / kg, approx. 3×10 13 vg / kg, approx. 5×10 13 vg / kg, approximately 7×10 13 vg / kg, approximately 1×10 14 vg / kg, approx. 3×10 14 vg / kg, or approximately 5 × 10 14 It is administered systemically at a dose of vg / kg. In some embodiments, the AAV vector is approximately 6.7 × 10⁻⁶. 13 vg / kg, approximately 1.1×10 13 vg / kg, or approximately 2.0 × 10⁻⁶ 13 It is administered systemically at a dose of vg / kg.

[0151] In some embodiments, the AAV vector is 1 × 10 13 vg / kg, 3 × 10 13 vg / kg, 5×10 13vg / kg, 7×10 13 vg / kg, 1 × 10 14 vg / kg, 3 × 10 14 vg / kg, or 5 × 10 14 It is administered systemically at a dose of vg / kg. In some embodiments, the AAV vector is 6.7 × 10⁶ 13 vg / kg, 1.1 × 10 13 vg / kg, or 2.0 × 10 13 It is administered systemically at a dose of vg / kg.

[0152] In some embodiments, the AAV vector is approximately 1 × 10⁶ AAV vectors per kilogram (vg) of the subject's total body weight. 13 ~5×10 14 The vector genome is administered intravenously at a dose of (vg)(vg / kg). In some embodiments, the AAV vector is approximately 1 × 10⁻⁶ 13 ~5×10 14 It is administered intravenously at a dose of vg / kg. In some embodiments, the AAV vector is approximately 5 × 10⁻¹⁴. 13 ~3×10 14 It is administered intravenously at a dose of vg / kg. In some embodiments, the AAV vector is approximately 1 × 10⁻⁶ 13 ~1 × 10 14 It is administered intravenously at a dose of vg / kg. In some embodiments, the AAV vector is approximately 1 × 10⁻¹⁶ 13 Less than vg / kg, approximately 3 x 10 13 Less than vg / kg, approximately 5 x 10 13 Less than vg / kg, approximately 7 x 10 13 Less than vg / kg, approximately 1 × 10⁻⁶ 14 Less than vg / kg, approximately 3 x 10 14 Less than vg / kg, or approximately 5 × 10 14 It is administered intravenously at doses less than vg / kg.

[0153] In some embodiments, the AAV vector is approximately 6.7 × 10⁻⁶. 13 ~2×10 14 It is administered intravenously at a dose of vg / kg. In some embodiments, the AAV vector is approximately 6.7 × 10⁻⁶. 13 ~Approx. 1.1×10 14It is administered at a dose of vg / kg.

[0154] In some embodiments, the AAV vector is approximately 1 × 10⁻⁶ 13 vg / kg, approx. 3×10 13 vg / kg, approx. 5×10 13 vg / kg, approximately 7×10 13 vg / kg, approximately 1×10 14 vg / kg, approx. 3×10 14 vg / kg, or approximately 5 × 10 14 It is administered intravenously at a dose of vg / kg. In some embodiments, the AAV vector is approximately 6.7 × 10⁻⁶. 13 vg / kg, approximately 1.1×10 13 vg / kg, or approximately 2.0 × 10⁻⁶ 13 It is administered intravenously at a dose of vg / kg.

[0155] In some embodiments, the AAV vector is 1 × 10 13 vg / kg, 3 × 10 13 vg / kg, 5×10 13 vg / kg, 7×10 13 vg / kg, 1 × 10 14 vg / kg, 3 × 10 14 vg / kg, or 5 × 10 14 It is administered intravenously at a dose of vg / kg. In some embodiments, the AAV vector is 6.7 × 10⁶ 13 vg / kg, 1.1 × 10 13 vg / kg, or 2.0 × 10 13 It is administered intravenously at a dose of vg / kg.

[0156] In some embodiments, the therapeutically effective dose of AAV virion is approximately 1 × 10⁻¹⁶ AAV virion per kilogram (vg) of the subject's total body weight. 12 ~Approx. 5×10 14 The vector genome is (vg)(vg / kg). In some embodiments, the therapeutically effective dose is approximately 1 × 10⁻⁶ 13 ~Approx. 5×10 14 The value is vg / kg. In some embodiments, the therapeutically effective dose is approximately 5 × 10⁻⁶. 13 ~Approx. 3×10 14The value is vg / kg. In some embodiments, the therapeutically effective dose is approximately 5 × 10⁻⁶. 13 ~Approx. 1×10 14 The value is vg / kg. In some embodiments, the therapeutically effective dose is approximately 1 × 10⁻⁶. 12 Less than vg / kg, approximately 3 x 10 12 Less than vg / kg, approximately 5 x 10 12 Less than vg / kg, approximately 7 x 10 12 Less than vg / kg, approximately 1 × 10⁻⁶ 13 Less than vg / kg, approximately 3 x 10 13 Less than vg / kg, approximately 5 x 10 13 Less than vg / kg, approximately 7 x 10 13 Less than vg / kg, approximately 1 × 10⁻⁶ 14 Less than vg / kg, approximately 3 x 10 14 Less than vg / kg, or approximately 5 × 10 14 It is vg / kg.

[0157] In some embodiments, the therapeutically effective dose of AAVvirion is approximately 6.7 × 10⁻⁶. 13 ~2×10 14 The value is vg / kg. In some embodiments, the AAV billion is approximately 6.7 × 10⁻⁶. 13 ~Approx. 1.1×10 14 It is administered at a dose of vg / kg.

[0158] In some embodiments, the therapeutically effective dose of AAV virion is approximately 1 × 10⁻⁶. 13 vg / kg, approx. 3×10 13 vg / kg, approx. 5×10 13 vg / kg, approximately 7×10 13 vg / kg, approximately 1×10 14 vg / kg, approx. 3×10 14 vg / kg, or approximately 5 × 10 14 The value is vg / kg. In some embodiments, the therapeutically effective dose is approximately 6.7 × 10⁻⁶. 13 vg / kg, approximately 1.1×10 13 vg / kg, or approximately 2.0 × 10⁻⁶ 13 It is vg / kg.

[0159] In some embodiments, the therapeutically effective dose of AAV virion is 1 × 10⁻⁶ 12vg / kg, 3 × 10 12 vg / kg, 5×10 12 vg / kg, 7×10 12 vg / kg, 1 × 10 13 vg / kg, 3 × 10 13 vg / kg, 5×10 13 vg / kg, 7×10 13 vg / kg, 1 × 10 14 vg / kg, 3 × 10 14 vg / kg, 5×10 14 vg / kg, 7×10 14 vg / kg, 1 × 10 15 vg / kg, 3 × 10 15 vg / kg, 5×10 15 vg / kg, or 7×10 15 The value is vg / kg. In some embodiments, the therapeutically effective dose is 6.7 × 10⁻⁶ 13 vg / kg, 1.1 × 10 13 vg / kg, or 2.0 × 10 13 It is vg / kg.

[0160] definition The terms "lysosome-associated membrane protein 2" and "LAMP-2" are used interchangeably to refer to (1) an amino acid sequence having, preferably over a region of at least about 25, 50, 100, 200, 300, 400 or more amino acids or over the full length, an amino acid sequence identity of more than about 90%, such as 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or more, to the amino acid sequence encoded by LAMP-2 nucleic acid (see, e.g., GenBank accession numbers NM_002294.2 (isoform A), NM_013995.2 (isoform B), NM_001122606.1 (isoform C)) or to the amino acid sequence of a LAMP-2 polypeptide (see, e.g., GenBank accession numbers NP_002285.1 (isoform A), NP_054701.1 (isoform B), NP_001116078.1 (isoform C)), (2) an antibody produced against an immunogen comprising the amino acid sequence of a LAMP-2 polypeptide (e.g., a LAMP-2 polypeptide as described herein) or the amino acid sequence encoded by a LAMP-2 nucleic acid (e.g., a LAMP-2 polynucleotide as described herein), such as a polyclonal antibody, and binding to its conservatively modified variants, (3) an antisense strand corresponding to the nucleic acid sequence encoding a LAMP-2 protein and specifically hybridizing under stringent hybridization conditions to its conservatively modified variants, (4) a nucleic acid having, preferably over a region of at least about 25, 50, 100, 200, 500, 1000, 2000 or more nucleotides or over the full length, a nucleotide sequence identity of more than about 90%, preferably more than about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more, to a LAMP-2 nucleic acid (e.g., a LAMP-2 polynucleotide as described herein and a LAMP-2 polynucleotide encoding a LAMP-2 polypeptide as described herein), and polypeptide polymorphic variants, alleles, mutants, and interspecies homologs.

[0161] The terms "lysosome-associated membrane protein 2B" and "LAMP-2B" are interchangeable to: (1) an antibody produced against an immunogen having an amino acid sequence having more than 90% amino acid sequence identity, for example, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, or more, over a region of at least about 25, 50, 100, 200, 300, 400, or more amino acids, or over the entire length, to an amino acid sequence encoded by a LAMP-2B nucleic acid (e.g., NM_013995.2) or an amino acid sequence of a LAMP-2B polypeptide (e.g., NP_054701.1), or an amino acid sequence having more than 90% amino acid sequence identity, for example, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, or more, over a region of at least about 25, 50, 100, 200, 300, 400, or more amino acids, or over the entire length, to an amino acid sequence encoded by a LAMP-2B polypeptide (e.g., the LAMP-2B polypeptide described herein), for example This refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologs having a nucleic acid sequence having more than about 90%, preferably more than about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more nucleotide sequence identity over a region of at least about 25, 50, 100, 200, 500, 1000, 2000 or more nucleotides, or over the entire length, to (3) an antisense strand corresponding to a nucleic acid sequence encoding a LAMP-2B protein that binds to a polyclonal antibody and a conservatively modified variant thereof, and to (4) a LAMP-2B nucleic acid (e.g., a LAMP-2B polynucleotide and a LAMP-2B polypeptide encoding a LAMP-2B polypeptide as described herein) that specifically hybridizes to the conservatively modified variant under stringent hybridization conditions.

[0162] With respect to a protein (e.g., LAMP-2B), the term "functional variant" refers to a polypeptide sequence in which there are at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, or at least about 80 amino acids that retain one or more functional properties of the protein, or a fragment of the polypeptide sequence. For example, a functional variant of LAMP-2B is LAMP-2B (as defined herein) that retains one or more functions such as (1) regulation of human cardiomyocyte function (Chi et al. (2019) PNAS USA 116(2) 556-565), (2) improvement of metabolic and physiological functions in Danon disease (Adler et al. (2019) J. Am. College Cardiology S0735-1097(19) 31295-1), and / or (3) autophagy (Rowland et al. (2016) J. Cell Sci. (2016) 129, 2135-2143).

[0163] LAMP-2B has a luminal domain (residues 29-375), a transmembrane domain (residues 376-399), and a cytoplasmic domain (residues 400-410). See UniProt acceptance number P13473. The functions of LAMP-2B include chaperone-mediated autophagy, a process that mediates the lysosomal degradation of proteins as part of the normal metabolic turnover of proteins that respond to various stresses and have long biological half-lives (Cuervo et al. Science 273:501-503 (1996), Cuervo et al. J. Cell Sci. 113:4441-4450 (2000), Bandyopadhyay et al. Mol. Cell. Biol. 28:5747-5763 (2008), Li et al. Exp. Cell Res. 327:48-56 (2014), Hubert et al. Biol. Open 5:1516-1529 (2016)). LAMP-2B can target GAPDH and MLLT11 for lysosomal degradation. LAMP-2B may be required for the fusion of autophagosomes and lysosomes during autophagy. Cells lacking LAMP2 express normal levels of VAMP8 but are unable to accumulate STX17 on autophagosomes, which is the most compelling explanation for the lack of fusion between autophagosomes and lysosomes. LAMP-2B may be required for the normal degradation of autophagosome contents. LAMP-2B may be required for the efficient MHCII-mediated presentation of exogenous antigens through its function in lysosomal proteolysis, where antigenic peptides generated by proteases in the endosomal / lysosomal compartment are captured by nascent MHCII subunits (Crotzer et al. Immunology 131:318-330 (2010)).

[0164] Therefore, functional variants of LAMP-2B include fragments of LAMP-2B that can mediate any of the functions described above. In some embodiments, the functional fragment of LAMP-2B includes one or more of the lumen domain, transmembrane domain, and cytoplasmic domain. In some embodiments, the functional variant of LAMP-2B includes one or more C-terminal or N-terminal deletions compared to native LAMP-2B. In some embodiments, the functional variant of LAMP-2B includes one or more internal deletions compared to native LAMP-2B.

[0165] The term “identical” or “identity” percentage in relation to two or more nucleic acid or polypeptide sequences means that, when compared and aligned for maximum match across a comparison window or designated region, as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection, two or more sequences or subsequences are identical or have a specific percentage of the same amino acid residues or nucleotides (i.e., sharing at least about 80% identity, e.g., at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity across a specific region with respect to a reference sequence, e.g., a LAMP-2 polynucleotide or polypeptide sequence described herein). In such cases, such sequences are considered “substantially identical.” This definition also refers to the complementation of test sequences. Preferably, the identity exists in a region of at least about 25 amino acids or nucleotides of the reference sequence, for example, a region of 50, 100, 200, 300, or 400 amino acids or nucleotides, or over the entire length.

[0166] In sequence comparison, typically, one sequence acts as a reference sequence, and the test sequence is compared against it. When using a sequence comparison algorithm, the test sequence and reference sequence are entered into a computer, subsequence coordinates are specified as needed, and sequence algorithm program parameters are specified. Default program parameters can be used, or alternative parameters can be specified. The sequence comparison algorithm then calculates the sequence identity percentage of the test sequence relative to the reference sequence based on the program parameters. For sequence comparison of nucleic acids and proteins, the BLAST and BLAST2.0 algorithms and default parameters are used.

[0167] As used herein, the “comparison window” includes a reference to one segment of consecutive positional numbers selected from the group consisting of 20 to 600, typically about 50 to about 200, and more typically about 100 to about 150, where the two sequences may be compared after optimally aligning reference sequences of the same consecutive positional number as a given sequence. Sequence alignment methods for comparison are well known in the art. Optimal sequence alignment for comparison can be performed, for example, by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), the similarity search method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA from the Wisconsin Genetics Software Package (Genetics Computer Group, 575 Science Dr., Madison, Wl)), or by manual alignment and visual inspection (see, for example, Ausubel et al., eds., Current Protocols in Molecular Biology (1995 supplement)). Examples of suitable algorithms for determining sequence identity percentages and sequence similarity percentages are the BLAST and BLAST2.0 algorithms, which are described in Altschul et al., J.Mol.Biol.215:403-410 (1990) and Altschul et al., Nucleic Acids Res.25:3389-3402 (1977), respectively. Software for performing BLAST analysis is publicly available from the National Center for Biotechnology Information (ncbi.nlm.nih.gov / ).

[0168] An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross-reactive with an antibody produced against the polypeptide encoded by the second nucleic acid, as described below. Therefore, the polypeptide is typically substantially identical to the second polypeptide if, for example, the two peptides differ only in conserved substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize with each other under stringent conditions. Yet another indication that two nucleic acid sequences are substantially identical is that the sequences can be amplified using the same primers.

[0169] As used herein, “administration” means local and systemic administration, including, for example, enteral administration, parenteral administration, pulmonary administration, and topical / transdermal administration. The routes of administration of the compounds used in the methods described herein (e.g., polynucleotides encoding one or more LAMP-2 isoforms) include, for example, oral (per os(PO)) administration, nasal or inhalation administration, administration as a suppository, topical contact, transdermal delivery (e.g., via a transdermal patch), subarachnoid (IT) administration, intravenous ("iv") administration, intraperitoneal ("ip") administration, intramuscular ("im") administration, intrafocal administration, or subcutaneous ("sc") administration, or sustained-release devices, such as implantation of a small osmotic pump, or administration of a depot formulation. Administration may be by any route, including parenteral and transmucosal (e.g., oral, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intrarenal, intraurethral, ​​intracardiac, intracoronary, intramyocardial, intradermal, epidural, subcutaneous, intraperitoneal, intraventricular, ionophoretic, and intracranial methods. Other delivery methods include, but are not limited to, liposomal formulations, intravenous infusion, and transdermal patches.

[0170] The term "correction" refers to a change in a clinical parameter relative to the baseline level of the subject, which normalizes that parameter to a level equal to or approximately equal to the parameter level observed in individuals without Danon disease.

[0171] The term "improvement" refers to a change in a clinical parameter relative to the baseline level of the subject, which increases (or decreases) that parameter to a level substantially higher (or lower) than the parameter level observed in the subject before treatment administration. For example, improvement may include a reduction in the size or number of autophagynetic vacuoles in the subject's heart.

[0172] The terms “systemic administration” and “to be administered systemically” refer to methods of administering a compound or composition to a mammal such that the compound or composition is delivered via the circulatory system to sites within the body, including the site of pharmacokinetic action. Systemic administration includes, but is not limited to, oral administration, intranasal administration, rectal administration, and parenteral administration (e.g., intramuscular, intravenous, intra-arterial, transdermal, and subcutaneous, or other methods outside the gastrointestinal tract).

[0173] The term "simultaneous administration" or "co-administration," when used, for example, in relation to a compound (e.g., LAMP-2 polynucleotide) and / or its analogues and another activator, refers to the administration of both the compound and / or analogue and the activator so that they can achieve their physiological effects simultaneously. However, these two drugs do not necessarily have to be administered together. In certain embodiments, the administration of one drug may precede the administration of the other. Simultaneous physiological effects do not necessarily require both drugs to be present in circulation at the same time. However, in certain embodiments, co-administration typically results in both drugs being present simultaneously in the body (e.g., in plasma) at a significant proportion of their maximum serum concentrations for any given dose (e.g., 20% or more, e.g., 30% or 40% or more, e.g., 50% or 60% or more, e.g., 70% or 80% or 90% or more).

[0174] The term "therapeutic dose" refers to the amount of gene therapy vector and / or dosage, and / or drug regimen required to produce a desired outcome, such as increased expression of one or more LAMP-2 isoforms, that is sufficient to reduce the final severity of a disease characterized by autophagy impairment or deficiency (e.g., Danon disease).

[0175] The term "effective dose" refers to the amount and / or dosage of a gene therapy vector and / or drug regimen required to produce the desired result, such as the immunosuppressive effect of an immunosuppressant.

[0176] The phrase "administer" refers to the act of controlling and / or authorizing the administration of the drug / compound in question to a subject, carried out by a medical professional (e.g., a physician) or the person managing the subject's medical care. Administering may include diagnosing and / or determining an appropriate treatment or prophylactic regimen for the subject, and / or prescribing a specific drug / compound. Such prescribing may include, for example, drafting prescription forms or annotating medical records.

[0177] As used herein, the terms “to treat” and “to cure” mean delaying the onset, slowing or reversing the progression, reducing the severity, or alleviating or preventing any of the symptoms of a disease or condition to which these terms apply, or one or more symptoms of such disease or condition. The terms “to treat” and “to cure” also include preventing, alleviating, improving, reducing, suppressing, eliminating, and / or reversing one or more symptoms of a disease or condition.

[0178] The term "alleviate" means reducing or eliminating one or more symptoms of the pathology or disease, and / or reducing the rate of onset or delay of onset or the severity of one or more symptoms of the pathology or disease, and / or preventing the pathology or disease. In certain embodiments, the alleviation or elimination of one or more symptoms of the pathology or disease may include, for example, a measurable sustained increase in the expression level of one or more isoforms of LAMP-2.

[0179] As used herein, the phrase “essentially consisting of” means a genus or species of active pharmaceutical product listed in the method or composition, and may further include other agents that, on their own, do not have substantial activity for the listed symptoms or purposes.

[0180] The terms "subject," "individual," and "patient" are interchangeable in referring to human subjects.

[0181] The terms "gene transfer" or "gene delivery" refer to methods or systems for reliably inserting foreign DNA into a host cell. Such methods may result in transient expression of unintegrated introduced DNA, extrachromosomal replication and expression of introduced replicons (e.g., episomes), or integration of introduced genetic material into the host cell's genomic DNA.

[0182] The term "vector", when it appears alone, is used herein to refer to a nucleic acid molecule that can introduce or transport another nucleic acid molecule. The introduced nucleic acid is generally ligated to, for example inserted into, the vector nucleic acid molecule. The vector may contain sequences that direct self - replication or reverse transcription within the cell, or may contain sequences sufficient to allow integration into the host cell DNA. The term "vector" includes gene therapy vectors. As used herein, the term "gene therapy vector" refers to a vector (such as an AAV virion) that can be used in gene therapy and can deliver, for example, a polynucleotide sequence encoding a therapeutic polypeptide to a target. A gene therapy vector may contain a therapeutically active polypeptide, such as LAMP - 2B, or a nucleic acid molecule ("transgene") encoding another gene useful for replacement gene therapy when introduced into a target. Useful vectors include, but are not limited to, viral vectors. The terms "AAV vector" and "AAV virion" are used interchangeably herein to refer to a vector genome packaged in an AAV capsid.

[0183] As used herein, the term "expression cassette" refers to a DNA segment that can drive the expression of a polynucleotide (transgene) encoding a therapeutically active polypeptide (such as LAMP - 2B) incorporated into the expression cassette under appropriate circumstances. When introduced into a host cell, the expression cassette can, inter alia, instruct the cell's machinery to transcribe the transgene into RNA, which is then usually further processed and ultimately translated into a therapeutically active polypeptide. An expression cassette can be included in a gene therapy vector. Generally, the term "expression cassette" excludes polynucleotide sequences 5′ of the 5′ ITR and 3′ of the 3′ ITR.

[0184] All patents, patent publications, and other publications referred to and identified herein are hereby incorporated by reference in their entirety for all purposes individually and expressly as if set forth herein. [Examples]

[0185] Example 1: Recombinant AAV9 vector expressing LAMP2B Recombinant AAV9 vectors expressing LAMP2B were generated using three plasmids and a helper virus-free system. Transient transfection of HEK293T-producing cells with the pAAV-LAMP2B transfer plasmid, pAAV-2 / 9 packaging plasmid, and pAd-Helper adenovirus helper plasmid generated recombinant AAV particles containing serotype 9 capsid protein and AAV2 ITR adjacent to a human LAMP2B expression cassette (AAV9.LAMP2B).

[0186] The structure of the AAV cis-transfer plasmid (pAAV-LAMP2B), as shown in Figure 1, includes a transgene expression cassette adjacent to the viral ITR region derived from AAV2. The expression cassette contains a human LAMP2B coding sequence driven by a chimeric promoter containing a CMV IE enhancer (CMV IEE), a chicken β-actin (CBA) promoter, chimeric chicken β-actin, and rabbit globin introns. The expression cassette also contains a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) and is terminated by a rabbit globin polyA signal (RGpA).

[0187] Example 2: Preclinical in vitro and in vivo efficacy studies In vitro studies were conducted using iPSC-derived cardiomyocytes from patients with Danon disease (DD), demonstrating a dose-dependent increase in LAMP2B expression and beneficial effects on mitochondrial membrane potential, a key cellular characteristic of cardiomyocytes in DD. Following the demonstration of in vitro phenotypic correction, in vivo studies of LAMP-2B gene therapy were conducted in a clinically significant calorie-restricted LAMP2 knockout (KO) mouse model.

[0188] Lamp2 KO mice were given phosphate-buffered saline (PBS) or 1 × 10⁶ at 2 months of age. 13 , 5×1013 , and 1 × 10 14 AAV9.LAMP2B was administered intravenously at a dose of vg / kg, followed by 6 weeks of alternate fasting, and evaluation was performed 3 months after treatment. As shown in Figures 2 and 3, a dose-dependent increase in human LAMP2B and a decrease in LC3-II (a marker of autophagy flux) were observed in organs particularly affected by DD, including the heart, liver, and skeletal muscle, of AAV9-treated KO mice.

[0189] As shown in Figure 4, administration of AAV9.LAMP2B resulted in 5 × 10⁶ days after treatment 3 months later. 13 vg / kg and 1 × 10⁻⁶ 14 Lamp2 KO mice treated with a dose of vg / kg showed improved cardiac ultrastructure, including a smaller number of visible autophagy vacuoles. 1×10 14 The cardiac ultrastructure of Lamp2 KO mouse cohort administered at vg / kg was significantly improved and similar to that of control WT animals. Conversely, KO mice administered only with PBS showed an increased number of vacuoles in the cardiac tissue. Invasive hemodynamics were performed before the end of the study to examine cardiac function. As shown in Figure 11, contractility was evaluated by invasive left ventricular pressure (dP / dt maximum and dP / dt minimum), and it was found to be significantly reduced in untreated PBS-controlled Lamp2 KO mice compared to WT controls. The mean dP / dt maximum and dP / dt minimum values ​​for WT mice were 7050 mmHg / s and -5550 mmHg / s, respectively. In LAMP2 KO mice, the mean dP / dt maximum and dP / dt minimum values ​​were 3656 mmHg / s and -3265 mmHg / s in the PBS-treated group (n=7), and 1 × 10⁻⁶ 13 For the group treated with AAV9.LAMP2B at vg / kg (n=7), the values ​​were 4197 mmHg / s and -3542 mmHg / s, and 5 × 10⁻⁶ 13 In the case of vg / kg (n=12), the values ​​are 5073 mmHg / s and -3905 mmHg / s, which is 1 × 10⁻⁶ 14 For vg / kg (n=11), the values ​​were 4729 mmHg / s and -3765 mmHg / s.

[0190] As shown in Figure 12, AAV9.LAMP2B significantly improved the ultrastructure of the heart in adult Lamp2 KO mice. As shown in Figure 13, a significant improvement in cardiac function was demonstrated by invasive hemodynamics at 3 months, with improvement observed at the maximum dose tested of 2 × 10⁶. 14 The response was dose-dependent across vg / kg. At this highest dose, cardiac hemodynamics were comparable to the wild-type phenotype, thus suggesting maximum efficacy and possibly the optimal effective dose. A significant decrease in liver enzymes suggested that improvement in liver abnormalities was also observed in AAV9-dose animals. The results of this study suggest that AAV9.LAMP2B-mediated gene therapy is safe and 2 × 10⁶ 14 We demonstrated that we successfully reversed established disease phenotypes in aged mice by improving cardiac physiology, autophagy flux, and hepatic abnormalities with an effective dose of vg / kg.

[0191] Example 3: Preclinical Pharmacology Safety assessments, including clinical pathology, histopathology, and immune responses to LAMP-2B gene therapy, were performed on Lamp2 KO mice. Serum chemistry panels showed no adverse outcomes in either PBS-controlled mice or mice administered the AAV9.LAMP2B vector. A significant increase in serum potassium (K+) levels was observed in untreated PBS-controlled KO mice compared to WT animals. Compared to PBS-injected Lamp2 KO control mice, levels increased by 5 × 10⁶. 13 vg / kg, 1 × 10 14 vg / kg, and 2 × 10 14In mice treated with vg / kg AAV9.LAMP2B, these K+ levels significantly decreased and returned to the expected range. Elevated serum potassium levels when serum creatine and blood urea nitrogen levels are normal may result from excessive muscle breakdown (Lehnhardt 2011). Therefore, the observed decrease in serum potassium with AAV9.LAMP2B administration indicates a reduction in myopathy in mice treated with LAMP-2B gene therapy, a key feature of DD. Histopathology of cardiac, hepatic, and skeletal muscle tissue did not show any remarkable changes in samples treated with AAV9.LAMP2B. In vivo distribution of the vector was examined by qPCR, revealing a significant distribution across organs throughout the body. The highest level of vector genome (vg) was found in the liver, with vg levels 10-fold lower in the heart and skeletal muscle compared to the liver, and 100-fold lower in the brain. The spleen and gonads showed the smallest distribution of vector genome. Quantification of transgene expression by mRNA estimation was performed at 1 × 10⁻⁶ levels. 14 vg / kg and 2 × 10 14 Mice administered vg / kg of AAV9.LAMP2B were validated in tissue subsets using RT-qPCR. On average, the heart had the highest levels of human LAMP2B mRNA, closely followed by the liver and skeletal muscle. The brain, lungs, kidneys, and gonads also showed moderate levels of human LAMP2B mRNA, with very low levels detected in the spleen at 6 months post-administration.

[0192] The preclinical studies described herein shall be conducted in accordance with Good Laboratory Practice (GLP), with a maximum of 3 × 10⁶ 14 No unexpected mortality, physical abnormalities, behavioral abnormalities, morphological abnormalities, hematological abnormalities, or biochemical abnormalities were observed in relation to the vg / kg dose. The results of this study demonstrate that AAV9.LAMP2B-mediated gene therapy is safe and provides sustained benefits in the DD phenotype in Lamp2 KO mice. This study shows a safe and effective profile for IV (intravenous) administration of LAMP-2B gene therapy, with a minimum effective dose of AAV9.LAMP2B being 5 × 10⁶. 13~1 × 10 14 The results show that the values ​​are within the range of vg / kg, demonstrating the clinical potential of LAMP-2B gene therapy for the treatment of Danon disease in humans.

[0193] Example 4: Preclinical Toxicology In addition, the 102-day non-GLP study compared the maximum dose (3 × 10) tested in the GLP mouse toxicity study. 14 Two-year-old non-human primates (NHPs) (cynomolgus macaques) were treated with a therapeutic vector (vg / kg). Animals were pre-screened for AAV9 neutralizing antibodies before shipment. All animals assigned to the treatment and vehicle control groups showed complete serokinetics (virus neutralization was not observed at 1:5, 1:20, and 1:80 dilutions). Two monkeys were treated with the therapeutic vector (3 × 10⁶). 14 Two monkeys were assigned to the vehicle control group (vg / kg). After administration (intravenous injection into the saphenous vein), the animals were evaluated at baseline and on days 3, 7, 15, 21, 30, 42, 50, 60, 91, and 102. There were no unexpected mortality rates or significant changes in body weight. For clinicopathology, blood samples were taken from both cohorts at multiple time points. A mild transient increase in transaminases and a simultaneous transient decrease in platelets (within the normal range) on day 7 were observed in the AAV9.LAMP2B injection group, with no pathological complications. Mild elevations of creatinine kinase and lactate dehydrogenase (within the normal range) were also observed on day 50 of the study, and there were no clinical signs of toxicity-related illness. No other significant treatment-related effects were observed in any other hematological or biochemical evaluations performed.

[0194] Example 5: Clinical study of LAMP-2B gene therapy 6.7 × 10 13 The initial dose of GC / kg was selected for the clinical study. The dose escalation approach was 6.7 × 10⁶. 13 GC / kg~2.0×10 14 This involves evaluating intermediate doses in GC / kg.

[0195] The dose units for preclinical studies evaluating AAV9.LAMP2B are expressed in vector genomes (vg) per kg of body weight. The clinical dose of AAV9.LAMP2B administered in this study is expressed in vector genome copies (GC) / kg, as this nomenclature is considered the best description of the investigational substance quantified during the manufacturing process. Both of these unit terms (GC / kg and vg / kg) are intended to describe the same entity in terms of transgene quantity.

[0196] This study will exclude subjects with high pre-existing anti-AAV9 serum neutralizing antibody titers (anti-AAV9 neutralizing antibody titer >1:40). Patients with findings of synthetic or cholestatic hepatic dysfunction (PT / INR >1.5×ULN, bilirubin >1.5×ULN) will also be excluded (transaminases elevated up to 10×ULN or GGT elevated up to 2×ULN are acceptable, as these are prominent components of DD and are thought to mainly reflect muscle abnormalities). Systemic corticosteroid therapy will be administered one day before AAV infusion, continued for several weeks after administration, and gradually tapered and discontinued 8-12 weeks after infusion.

[0197] Safety monitoring included frequent testing of liver enzymes (including transaminases, bilirubin, ALP, and coagulation parameters). Platelet and comprehensive coagulation profiles (including PT / aPTT / fibrinogen / D-dimer) were also evaluated to complement pathway components. Serum and whole blood were also obtained to assess the potential humoral and cellular immune responses to both viral capsid components and LAMP-2B.

[0198] Objectives and evaluation items Main purpose To characterize the safety and toxicity associated with the injection of rAAV9 capsids containing the human LAMP2B transgene (investigational drug). • Evaluate the scope of a single intravenous dose of the investigational drug in terms of safety, toxicity, and preliminary efficacy. • To determine whether infusion of the investigational drug induces transduction and gene expression (determined by evaluation of myocardial LAMP2B DNA, RNA, and protein) in the cardiomyocyte (and skeletal muscle) using endocardial myocardial biopsy, to determine whether there is correction of disease-related histological abnormalities (autophagocytic vacuoles, myofibrils intertwined arrangement), and to enable preliminary characterization of the degree of molecular and histological correction of cardiomyocytes. • To enable a preliminary assessment of clinical stability, determined by medical parameters, radiographic parameters, and cardiopulmonary exercise / physiological parameters, approximately 8–12 weeks after investigational drug infusion (similar assessments will be performed at subsequent points in time to evaluate secondary objectives, as described later).

[0199] Secondary purpose To determine the percentage of patients who, as determined by medical evaluation, X-ray assessment of cardiac structure and function, and cardiopulmonary exercise / physiological parameters, experienced sustained improvement (over 6 months to 3 years after infusion of the investigational drug), stabilization (or a reduced rate of deterioration compared to historical controls) in cardiovascular pathophysiology following infusion of the investigational drug. Determine the percentage of patients whose cardiomyocytes contain corrected LAMP2B gene and / or protein and whose DD-related histological abnormalities have improved, and quantify, where possible, the degree of genetic and histological correction in the cardiomyocytes. To determine and characterize the immune response to the investigational drug (immunogenicity), including evaluation of humoral (antibody) and cellular (T lymphocyte) anti-AAV9 and anti-LAMP-2B protein activity. • To evaluate the percentage of patients who received the investigational drug and / or require and / or undergo subsequent heart transplantation, LVAD placement, implantation of an implantable cardioverter-defibrillator or pacemaker, electrophysiological resection for cardiac conduction abnormalities, or subsequent hospitalization due to heart failure. • To assess the overall survival of all patients, including those who received the investigational drug at the dose selected for subsequent evaluation, including 1-year and 3-year overall survival assessments.

[0200] exploratory purpose • To assess the potential correlation between evidence of molecular correction and evidence of histological correction in cardiomyocytes using parameters for clinical stabilization or improvement, and to assess the potential correlation between molecular / histological correction in cardiomyocytes and evidence of the LAMP2B gene / protein in skeletal muscle and blood. • Evaluate serological markers of muscle injury (including CPK and transaminase) and serological markers of congestive heart failure (including BNP and high-sensitivity troponin) to determine if early improvement (i.e., 8–12 weeks) of these blood markers may be a potential substitute for clinical, structural, and histological correction of DD. To evaluate patient-reported outcomes / quality of life (PRO / QOL) in patients treated with the investigational drug, using the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) and PedsQL. • Assess the presence and extent of improvement or stabilization (or reduced rate of deterioration compared to historical controls) in non-cardiovascular aspects of DD, including evaluation of neuromuscular and ocular function.

[0201] Evaluation items Safety evaluation items The safety and tolerability evaluation items are as follows: • Overall and severity-specific incidence rates of adverse events (TEAEs) and SAEs that occurred during treatment. • Overall and severity-specific incidence of TEAEs and SAEs that the principal investigator considered to be at least potentially associated with AAV9.LAMP2B. The percentage of patients requiring cardiac intervention, including heart transplantation, implantation of an implantable cardioverter-defibrillator or pacemaker, electrophysiological resection for cardiac conduction abnormalities, or subsequent hospitalization due to heart failure. Characterization of the immune response to AAV9.LAMP2B, as demonstrated by antibodies or T lymphocytes that react to AAV9 or LAMP2B proteins. • Findings of hepatotoxicity based on changes from baseline in hepatic transaminases (AST and ALT), GGT, bilirubin, and ALP. • Findings of coagulation disorder based on changes from baseline in platelet count, prothrombin time (PT, or international normalized ratio (INR)), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, thrombin-antithrombin complex (TAT), and complement components (complement 3 (C3), complement 4 (C4), and serum membrane invasion complex (sC5b-9)). • Changes from baseline for the following items: - Vital signs measurements. - Safety clinical test results. - Physical examination findings.

[0202] Effectiveness evaluation items Efficacy endpoints include assessment of clinical improvement and stabilization (or reduced rate of deterioration compared to historical controls) in cardiovascular pathophysiology, determined by medical evaluation, radiographic assessment of cardiac structure and function, and cardiopulmonary exercise / physiological parameters. Preliminary evaluation of efficacy endpoints will be performed during the initial safety-focused follow-up period (first 8–12 weeks after administration of the investigational drug) and during the more sustained follow-up period (6 months–3 years).

[0203] Research design This is a non-randomized, open-label, Phase I trial in patients with DD.

[0204] During this Phase I trial, approximately 11 to 23 patients will receive a single intravenous dose of the investigational drug (IP), and the patient cohort will be progressively administered AAV9.LAMP2B at increasingly higher dose levels according to the guidelines detailed below. Sites that have not administered IP may participate in this trial. These sites will conduct initial screening and follow-up visits after IP administration. IP administration and subsequent follow-up visits will be conducted at the site where IP is administered. This is intended to reduce the burden of travel for patients and their families across a wide area.

[0205] We plan to investigate three dose levels in six different cohorts. Dosing a cohort to evaluate a given dose in a pediatric population (8–14 years) is only feasible if it is determined that less than 33% of patients in the adult cohort at the equivalent dose experienced dose-limiting toxicity (DLT). Dosing a cohort to administer a higher dose to adult or pediatric patients is only feasible if it is determined that less than 33% of patients in the previous low-dose cohort experienced DLT. To enable DLT assessment, patients must have received the intended dose of IP and remain follow-upable for eight weeks post-IP infusion (excluding patients with a fatal AE considered to be related to the investigational drug during the first eight weeks post-infusion).

[0206] Administration at a given dose level in pediatric patients (8–14 years) will only be initiated while awaiting determination of dose-level safety in the elderly (adult and 15–17 years) cohorts. Figure 8 shows the complete sequence of planned enrollments in a cohort under scenarios where DLTs are not identified. Figure 9 shows the enrollment sequence within any given cohort. Decisions regarding cohort expansion, opening of subsequent cohorts (including increasing or changing investigational drug doses), and recommendations for doses to be evaluated in subsequent clinical development will be made by the IDSMC based on the safety profiles and potential direct benefits identified in the preceding cohorts. Additional regularly scheduled reviews of investigational drug safety by the IDSMC will be conducted for patients in each study cohort after the initial 8-week DLT evaluation period.

[0207] Investigational drug The investigational drug (AAV9.LAMP2B), as shown in Figure 1 and described in Example 1, is a gene therapy product comprising a human LAMP2B transgene and an AAV9 capsid containing an ITR element, CMV IEE, CBA promoter, CBA, a CAG promoter including rabbit globin introns, WPRE, and RGpA.

[0208] Dosage form The composition of AAV9.LAMP2B is an active ingredient formulated in a buffer suitable for injection (200 mM NaCl, 10 mM NaH2PO4, 1% (w / v) sucrose, 0.01% poloxamer 188, pH 7.2 ± 0.1) ([3.0~6.0 × 10 13 It consists of recombinant AAV9.LAMP2B virus particles at a concentration of [vg / mL] that can transduce target cells and express the therapeutic protein LAMP2B. AAV9.LAMP2B is supplied to the clinical setting as a frozen product, and the final volume of AAV9.LAMP2B dosage is based on the patient's body weight in kilograms (kg) and the calculated vector genome (vg) copies of AAV9 per milliliter (mL).

[0209] Dosage to be investigated During this Phase I trial, 11–23 patients will receive a single IV dose of the investigational drug, and AAV9.LAMP2B will be administered to up to three specific cohorts of adult and pediatric patients at dose levels according to the following guidelines. Initiation of a cohort to evaluate a given dose in the pediatric population (8–14 years) is only permissible if it is determined that less than 33% of patients in the adult cohort at equivalent doses experienced dose-limiting toxicity (DLT). The three AAV9.LAMP2B dose levels will be investigated according to the dose-escalation design, as follows: Cohort 1: Adults and 15-17 year olds: 6.7 × 10 13 GC / kg(n=3)* Cohort 2: Adults and 15-17 year olds: 1.1 × 10 14 GC / kg (n=2~4) Cohort 3: Adults and 15-17 year olds: 2.0 × 10 14 GC / kg (n=2~4) Cohort 1A: Children 8-14 years old: 6.7 × 10 13 GC / kg (n=2~4) • Cohort 2A: Children 8-14 years: 1.1 × 10 14 GC / kg (n=2~4) Cohort 3A: Children 8-14 years: 2.0 x 10 14 GC / kg (n=2~4) Cohort 1 enrolled three patients according to the previous protocol version.

[0210] Evaluation of AAV9.LAMP2B in pediatric patients (8–14 years) at prescribed dose levels should only be initiated while awaiting determination of the safety of dose levels in older populations (adults and those 15–17 years old who are generally capable of providing informed consent). AAV9.LAMP2B should be administered in doses based on total body weight. If the patient is obese (body mass index (BMI) >85%), IP may be administered in doses based on lean body mass (LBM) using the following Hume formula, according to the Centers for Disease Control and Prevention (CDC) growth chart: LBM = (0.32810 × W) + (0.33929 × H) - 29.5336

[0211] This trial excluded patients with pre-existing anti-AAV9 serum neutralizing antibody titers (≥1:40). Patients received prophylactic medication for anti-AAV immunogenic reactions along with rituximab, tacrolimus, and corticosteroids. Rituximab was administered before IP infusion. Tacrolimus was administered for 3 months, starting before IP administration. Corticosteroids were started the day before therapeutic vector administration, then administered daily until week 8 post-treatment, and subsequently tapered over 4 weeks before discontinuation. Incorporating tacrolimus and rituximab as part of an immunosuppressive regimen allows for an overall reduction in corticosteroid dosage.

[0212] Clinical safety profile of Cohort 1 In a cohort of three patients aged 15 years or older (Cohort 1), corticosteroids were administered in combination according to the protocol for 6.7 × 10⁶ days. 13 LAMP-2B gene therapy was administered at a dose of GC / kg. Subject characteristics are shown in Table 1. Tacrolimus was also administered to the second and third patients. The treatment regimens and relative LAMP2B expression are shown in Table 2. No significant anti-drug antibody (ADA) response to LAMP2B was observed.

[0213] The patient presented with several systemic symptoms (nausea, vomiting, abdominal pain, and low-grade fever, etc.) a few days after IP administration. As expected, the patient developed an immune response after IP administration. This immune response was associated with decreased blood cell counts (platelets, white blood cells), elevated transaminases, and elevated levels of skeletal muscle and cardiac-related enzymes and peptides. The decrease in platelet count, which occurred approximately 1-2 weeks after treatment, was associated with a corresponding increase in D-dimer and a decrease in C3 and C4 (complement portion). Decreased platelet count has been observed in other AAV gene therapy programs and is consistent with an acute complement-mediated immune response to the AAV9 capsid. Patients previously treated with LAMP-2B gene therapy continued corticosteroid administration and were not treated with eculizumab. The observed changes in platelet, D-dimer, and C3 / C4 levels improved after a few days.

[0214] Elevations in aspartate transaminase (AST) and alanine aminotransferase (ALT) have been demonstrated in other AAV gene therapy programs. The observed increases in AST / ALT were not associated with elevated bilirubin levels beyond the normal range or clinical signs / symptoms of hepatobiliary disease. Elevations in GGT (a liver enzyme that, unlike AST / ALT, is not affected by skeletal muscle damage) were milder and did not exceed levels greater than 5 times baseline. EliSpot assays were negative for both the AAV9 capsid and LAMP2B transgene in the first three patients in Cohort 1. These increases in AST and ALT are primarily attributable to skeletal muscle, as the increase in GGT from baseline was relatively lower than the increases in AST and ALT from baseline. This is also seen in the associated increases in CPK. Two of the three patients in Cohort 1 developed skeletal muscle weakness consistent with steroid-induced myopathy. Skeletal muscle weakness recovered upon tapering and discontinuation of corticosteroids. At 6, 9, and 12 months after administration, the patient was stable at home.

[0215] (Table 1) TIFF2023552443000027.tif49148

[0216] (Table 2) TIFF2023552443000028.tif113148

[0217] Gene expression and efficacy endpoints for Cohort 1 In a cohort of three patients aged 15 years or older (Cohort 1), corticosteroids were administered in combination according to the protocol for 6.7 × 10⁶ days. 13 LAMP-2B gene therapy was administered at a dose of GC / kg. After treatment with LAMP-2B gene therapy, vector DNA copy number was analyzed as shown in Figure 5. As shown in Table 2, all three patients, including patient 1 with limited compliance to the immunosuppressive regimen, showed evidence of cardiac LAMP2B expression by Western blotting and immunohistochemistry. Patients 1002 and 1005, who showed good compliance to the immunosuppressive regimen, demonstrated improvement in clinical biomarkers along with high levels of cardiac LAMP2B expression. 6.7 × 10⁶ 13 Cardiac biopsies from patients treated with a systemic dose of gc / kg showed that LAMP2B gene expression was present in 68–92% of cells at 9 and 12 months compared to normal as determined by immunohistochemistry (IHC) in one patient, and at up to 61% of normal LAMP2B protein expression as measured by Western blot evaluation. As shown in Figure 6, patient 1002 showed robust cardiac expression of LAMP2 after treatment with LAMP-2B gene therapy. Patients 1002 and 1005 showed a consistent increase in percentage and level of IHC staining at later time points.

[0218] As shown in Figure 7, two of the three patients showed improvement in key clinical biomarkers consistent with improved cardiac function. Brain natriuretic peptide (BNP), a key marker of heart failure, improved (i.e., decreased) in all three patients, including over 50% in patients 1002 and 1005 (Figures 7B and 7C), confirming immunosuppressive regimen compliance. Creatine kinase myocardial bands (CPK-MB) either improved or stabilized in patients 1002 and 1005. Notably, visible improvement was observed in autophagocytic vacuoles, a characteristic feature of Danone pathology, upon evaluation by electron microscopy. As shown in Table 3, patients 1002 and 1005, whose immunosuppressive regimen compliance and follow-up were confirmed at 9 and 12 months, showed improvement in cardiac output as measured by invasive hemodynamics. Since patients with Danon disease do not improve on their own, the benefits observed in all three patients in this study are clinically significant and provide a transformative gene therapy approach to this otherwise devastating disease.

[0219] (Table 3) TIFF2023552443000029.tif53141

[0220] Definition of dose-limiting toxicity Dose-limiting toxicity (DLT) is defined as any occurrence of an adverse event (AE) within 8 weeks after administration of the investigational drug, as follows: • National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE), version 5.0, infusion-related reactions of grade 3 or higher. Despite supportive therapy, grade 4 transaminase elevation persists for more than two weeks in association with liver injury. • Grade 3 elevated transaminase levels that do not improve or recover with supportive regimens. Other grade 3 or higher adverse events, excluding grade 3 nausea / vomiting, diarrhea, constipation, fever, fatigue, or rash that resolve to less than grade 3 within 72 hours, or grade 3 clinical abnormalities unrelated to clinical symptoms that resolve to less than grade 3 within 2 weeks.

[0221] DLTs are determined independently of causal relationships attributable to the principal investigator. If there is a possible etiology unrelated to the investigational drug (e.g., Grade 3 pain following a car accident), the event may be deemed not to represent a DLT, but this requires evaluation by an IDSMC. Each patient's baseline values ​​are based on available clinical data obtained within 6 months prior to IP administration.

[0222] Dosage escalation procedure Enrollment within the cohort will be staggered so that the initial patient must be followed up for at least 8 weeks before subsequent patients in the cohort can receive IP. The addition of rituximab and tacrolimus is expected to reduce the immune response after IP administration. After suppression of the immune response is demonstrated, the 8-week period between subsequent patients in the cohort may be reduced with the consent of the IDSMC. Each cohort will consist of at least two patients. If one of the first two patients in a cohort experiences DLT, two additional patients will be enrolled in that cohort. All patients in the preceding cohort should have been followed up for at least 8 weeks after IP infusion and there should have been evidence of recovery or stabilization of DLT in order to initiate subsequent (high-dose or pediatric) cohorts. Pediatric patients (8-14 years) at a given dose level will only be initiated while awaiting determinations of dose level safety in cohorts 1, 2, and 3 (adults and 15-17 years) of the dose level.

[0223] In the first two or three patients of Cohort 1, 6.7 × 10 13 If it is determined that LAMP-2B expression below therapeutic efficacy is achieved with GC / kg (low dose) administration, then Cohort 2 will be 1.1 × 10⁶ 14 Start with an intermediate dose of GC / kg. 6.7 × 10 13If GC / kg is considered to be below the therapeutic dose, 6.7 × 10 13 Do not initiate cohort 1A (children aged 8-14 years) with GC / kg dose. 1.1 × 10 14 After completing Cohort 2 (adults and 15-17 year olds) at the intermediate dose of GC / kg, and while awaiting safety review by IDSMC, 1.1 × 10 14 Enrollment in Cohort 2A (children aged 8-14 years) at the intermediate dose of GC / kg will be initiated. See Figure 8.

[0224] Administration of investigational drug The patient is to receive the AAV9.LAMP2B gene therapy drug via IV infusion on day 0, and the IP infusion is intended to be administered to the patient as a single dose. The patient will receive the investigational drug in an inpatient (hospitalized) setting at a facility with experience in investigational drugs for cardiovascular disorders. The patient will be hospitalized for 48-72 hours and may remain hospitalized for up to 14 days after the investigational drug infusion, after which they may be discharged at the discretion of the principal investigator in charge of treatment. Daily evaluations will continue until day 7 and may be extended at the discretion of the principal investigator.

[0225] Pre-treatment medications and combination therapies Prophylactic drugs for anti-AAV immunogenic reactions are administered before and after infusion of the investigational drug. In addition to corticosteroids, rituximab and tacrolimus are administered to suppress the immune response to IP.

[0226] Pre-treatment medications Premedication before rituximab infusion: • Acetaminophen - 15 mg / kg PO (maximum 1 g) • Diphenhydramine - 12.5~50 mg PO, or as per the product's package insert. • Rituximab: Patients are administered rituximab at a dose of 750 mg / m2 on days 14 and 7 prior to IP infusion. • Corticosteroids: If patients are given prednisone (oral or IV) at a dose of 1 mg / kg body weight starting the day before (-1 day) infusion of the investigational drug, then administered daily until 8 weeks post-treatment, then tapered over 4 weeks and discontinued by 3 months, and enhanced immunosuppressive therapy (i.e., rituximab, tacrolimus) is administered as a prophylactic treatment, the principal investigator may, at their discretion and using the sponsor's medical monitor, initiate tapering of corticosteroids earlier (including within the first 4 weeks after IP administration). -If prednisone causes unacceptable adverse events, or if prednisone is unavailable, methylprednisolone or dexamethasone may be used instead at an equivalent dose (0.8 mg / kg for methylprednisolone, or 0.15 mg / kg for dexamethasone). - Corticosteroid tapering may be extended for a period longer than 4 weeks in cases of elevated liver enzymes (bilirubin or transaminase) above baseline or other adverse events caused by the investigational drug. - Corticosteroid tapering may be initiated before week 8, as described above, at the discretion of the principal investigator, using the sponsor's medical monitor, in cases of unacceptable corticosteroid-related adverse events or enhanced prophylactic immunosuppression. -Medications administered concurrently to prevent corticosteroid complications may be given according to the site's guidelines and should include prophylactic medications for Pneumocystis jirobesi pneumonia (PCP), gastrointestinal ulcers, and constipation. If site guidelines are not available, these may include, but are not limited to, atovaquone or trimethoprim / sulfamethoxazole administered three times weekly, an H2 antagonist (i.e., ranitidine) or a proton pump inhibitor (i.e., omeprazole), and stool softeners (i.e., doxate) with or without laxatives. Tacrolimus: Administer tacrolimus orally to the patient once daily in two divided doses. Adjust the dosage as needed based on tacrolimus struff serum levels to maintain a level of 2-5 ng / mL, starting administration on day 7 and continuing for up to 3 months. Tacrolimus may be discontinued at the discretion of the principal investigator. • Supportive medications during corticosteroid administration: In accordance with the practices of the clinical trial site, patients will be administered prophylactic medications for Pneumocystis dirobesi pneumonia (PJP / PCP), gastrointestinal ulcers, and constipation. • Additional pre-treatment medications: These are not required before the infusion of the investigational drug, but may be considered if required by the site guidelines for AAV investigational drug infusion. Such medications may include acetaminophen (paracetamol) and / or histaminergic H1 or H2 antagonists.

[0227] Concomitant (supportive) medications: Additional supportive therapies may be administered, at the discretion of the principal investigator, before or after IP administration to prevent or treat adverse effects. These include, but are not limited to, the following: corticosteroids • In cases of complement activation, eculizumab. Prior to administration of eculizumab, patients must have received the meningococcal vaccine as appropriately recommended by the disease management center, depending on their age and health condition. The meningococcal vaccine may be administered at the clinical trial site prior to administration of the investigational drug. • In cases of coagulation disorders, transfusion of platelets or plasma products is necessary. • Antiemetics (such as ondansetron) • In cases of neutropenia, growth factors (such as G-CSF [Neupogen®]) may be used. • In the case of injection-related reactions, analgesics and anti-inflammatory drugs.

[0228] Patient Inclusion Criteria To be eligible to participate in the clinical trial, patients must meet all of the following criteria (and must not meet any of the exclusion criteria). 1. Diagnosis of DD with confirmed LAMP2 mutation. 2. Cardiac disorder demonstrated by at least one abnormal finding in ECG, echocardiography, gadolinium-enhanced cardiac MRI, or electrophysiological testing. 3. For cohorts 1, 2, and 3, participants are 15 years of age or older; for cohorts 1A, 2A, and 3A, participants are 8 to 14 years of age. 4. Male. 5. NYHA Class II or III. Patients with NYHA Class I are eligible if they are unable to walk more than 450 meters during the 6MWT. 6. Appropriate hematological function as defined below: a. Hemoglobin level of 10 g / dL or higher (6.2 mmol / L, Grade 1 anemia according to NCI CTCAE 5.0 edition). b. Absolute neutrophil count of 1,500 / mm3 or higher (1.5 × 10⁹ / L, neutropenia of grade 1 or lower). c. Platelet count of 75,000 / mm³ or higher (75 × 10⁹ / L, thrombocytopenia of grade 1 or lower). 7. Liver function as defined below: a. AST and ALT ≤ 10.0 × ULN, or GGT ≤ 2 × ULN (elevated transaminases in DD are thought to be due to widespread muscle damage; therefore, relatively high upper limits for these transaminases, consideration of GGT levels, and the presence of additional hepatic eligibility markers such as bilirubin and PT / INR). b. Serum bilirubin ≤ 1.5 × ULN (i.e., grade bilirubin increase). c. PT / INR ≤ 1.5 × ULN (in the absence of anticoagulants). d. Absence of cirrhosis on liver ultrasound. 8. The following renal function: Creatinine ≤ 1.5 × ULN (If creatinine is greater than 1.5 ULN, the modified Schwartz formula (for patients under 18 years of age) (Schwartz2009) is used, calculated by the modified MDRD formula (Stevens2006) for dietary therapy in renal disease, 50 mL / min / 1.73 m 2 (The above creatinine clearance or 24-hour urine collection is required.) 9. Ability to provide informed consent (for adult patients and parents / legal guardians of pediatric patients) and consent forms (for patients aged 15-17). 10. Ability to comply with clinical trial procedures, including investigational therapy and follow-up evaluation. During an 11.6 MWT (Workout of the Morning), I can walk more than 150 meters without assistance. 12. Patients have received the meningococcal vaccine as recommended by the disease management center, depending on their age and health condition.

[0229] Patient Exclusion Criteria Patients who meet any of the following criteria will be excluded from participation in the clinical trial. 1. IV therapy with a positive inotropic agent, vasodilator, or diuretic within 30 days prior to registration (i.e., the patient must be stable on oral medical therapy). 2. History of heart transplantation, or transplantation of other organs (lungs, liver, etc.). 3. Cardiac surgery, percutaneous cardiac intervention, or valve repair within 30 days prior to registration. 4. The existence or necessity of LVAD. 5. Myocardial infarction, unstable stenosis, stroke, or TIA within 90 days prior to registration. 6. Significant (greater than moderate) valve stenosis or regurgitation on echocardiography. 7. Mechanical ventilation is required. 8. Anti-AAV9 neutralizing antibody titer greater than 1:40. 9. Concurrent enrollment in any other clinical trial involving the use of an investigational drug for the treatment of CHF or cardiomyopathy. 10. Active hepatitis B or C infection (including patients with positive HBsAg, HBeAg, or a detectable HBV or HCV viral load). Patients with a history of fully recovered HBV or HCV are eligible. 11. A serious medical condition, including demonstrated HIV infection, active viral or other hepatitis, uncontrolled hypertension or diabetes, uncontrolled cardiac arrhythmia, or uncontrolled viral, bacterial or fungal infection. 12. Any contingent medical or psychiatric condition that, in the opinion of the principal investigator, would make the patient unsuitable for participation in the trial or would result in a higher risk than the acceptable risk for participation in the trial. 13. Active hematological or solid organ malignancies, excluding non-melanoma skin cancer or other cancers that have not invaded epithelial tissue. Patients who have not had an active malignancy in the past three years, have previously had a solid organ malignancy resected, or have been treated for a hematological malignancy may be eligible. 14. Contraindications to the use of tacrolimus, including hypersensitivity to tacrolimus or HC-60 (polyoxyl 60 hydrogenated castor oil).

[0230] Exam period Patients will be screened and evaluated approximately 60 days before the administration of the investigational drug on day 0. All patients will be followed up for 36 months after administration of the investigational drug with the assistance of this protocol. Overall survival will be assessed, and patients who choose to discontinue other components of follow-up (this will be strongly prevented unless their health condition has deteriorated to the point of being contraindicated) will be given the option to remain in contact with the clinical trial staff for assessment of their overall health and survival. After the end of the follow-up period, patients will enter a long-term follow-up (LTFU) study, allowing for further follow-up for an additional 2–5 years after IP administration.

[0231] Long-term follow-up Following the Phase I safety endpoint assessment (first 8–12 weeks after infusion) and subsequent follow-up (first 3 years after infusion), continuous follow-up of safety and toxicity (i.e., AEs), overall survival, overall health status including need for heart transplantation, and other adverse health outcomes will be conducted periodically for a further 2–5 years (totaling 5–8 years, including the 3-year follow-up specified in this study). A 5-year long-term follow-up is planned, but if no serious AEs attributable to the investigational drug are identified during the first 2 years, a re-evaluation will be conducted.

[0232] If it is determined that no serious adverse drug reactions are identified during this study, a long-term follow-up will be planned for an additional two years (up to a maximum of five years), depending on the degree, severity, and recovery of any adverse events related to the investigational drug.

[0233] Event Schedule and Clinical Trial Procedures Event Schedule The investigational drug will be administered via intravenous infusion on day 0. Following the infusion, the patient will remain hospitalized or in-patient for at least 48–72 hours and up to 14 days, at the clinical discretion of the principal investigator. After IP infusion, the patient must attend clinical trial visits at the frequencies outlined in Figures 10A–10D. Evaluations will be performed daily for 7 days following the infusion of the investigational drug. Daily evaluations may be continued beyond day 7.

[0234] Follow-up visits involve a series of clinical evaluations, laboratory evaluations, cytochemical and genetic evaluations, cardiac imaging evaluations, and cardiac physiological evaluations, conducted several days, weeks, months, and years after the infusion of the investigational drug. Endocardial myocardial biopsy (performed by insertion of a central venous access catheter into the right ventricle) and skeletal muscle biopsy are also required before the infusion of the investigational drug and at selected points after the infusion.

[0235] Evidence in cardiomyocytes, including follow-up on the LAMP2B gene and protein (and histological evaluation of DD histology, including quantification of autophagy vacuoles), will be performed by endocardial myocardial biopsy at 8 weeks post-infusion, as well as at 6, 12, and 36 months. Additional minimally invasive assessments, including skeletal muscle biopsy, LAMP2B blood levels (plasma (LAMP-2B protein) and mononuclear cells (LAMP2B DNA)), and evaluation of other serological and radiographic parameters of cardiomyopathy and CHF, will be evaluated with the exploratory intent of identifying potential surrogate markers of molecular and histological improvement in the myocardium, as detailed below. A detailed event schedule is presented in Figures 10A-10D, with footnotes as follows. 1. Screening visits will be evaluated over a 60-day period. Evaluations performed as part of standard treatment prior to enrollment may be used as screening evaluations in this study, and it is not necessary to perform the evaluations again (based on the judgment of the principal investigator after consultation with the sponsor). 2. A baseline visit assessment may be performed after the patient has completed the screening visit and met all inclusion and exclusion criteria. All assessments must be completed on day -1 and before administration of the investigational drug. A baseline visit assessment does not need to be performed before initiating treatment with rituximab and tacrolimus. 3. During the screening visit, the comprehensive medical history will include relevant cardiovascular history and other potential disease-related history, such as hospitalizations and cardiac interventions, and the family history of the disease will also be recorded. 4. Concomitant medications and procedures during the screening visit and on day -1 shall include all medications and procedures taken in the past 30 days. During the follow-up visit, this should include all medications and procedures taken since the most recent prior evaluation. 5. Height will be measured once during the screening visit, and then once a year thereafter. 6. Quality of life / patient-reported outcome questionnaires include KCCQ-12 and PedsQL. 7. Daily clinical laboratory evaluation from day 1 to day 7. 8. Clinical laboratory evaluation will be performed up to three times a week. 9. Serum membrane invasion complex (sC5b-9) testing is required at the time specified in the protocol after administration of the investigational drug. This test may be performed at additional time points or more frequently, depending on the patient's clinical condition and at the discretion of the principal investigator. 10. Viroserology during screening visits should include HIV, HBV, HCV viral load, and a comprehensive HBV antigen / antibody panel including HBsAg, HBeAg, and HBsAb. 11. Cardiac serology includes potential markers of CHF, including BNP, CK-MB, and troponin-I levels. 12. The immune response to the investigational drugs (AAV9 and LAMP-2B) will be evaluated in serum (anti-drug antibodies (ADA), IgG, IgM) and peripheral blood T lymphocytes (ELISpot). 13. Collect whole blood, process it into serum, plasma, and PBMCs (only for screening evaluations), and store it for potential exploratory assays, including the assessment of LAMP2 levels in serum and blood cells. The trial ICF will provide patients with the opportunity to submit or withhold consent that stored samples may be used for potential additional future research not specified in the protocol. 14. Saliva, urine, stool, and blood (plasma) samples for screening are collected after administration of the investigational drug to assess vector particle detachment. Evaluation of each fluid / substance is continued as instructed until two negative evaluations are obtained for a given fluid / substance (or when the vector levels reach a low or negligible level and become level), at which point no further evaluation is required. 15. Gene sequencing to identify and define LAMP2 mutations shall be performed using an arrhythmia and cardiomyopathy panel in either saliva or blood (mononuclear cells). If the LAMP2 genotype is not defined as pathogenic, LAMP2 protein evaluation shall be performed using isolated peripheral blood mononuclear cells or biopsy tissue to confirm LAMP2 deficiency. 16. Gadolinium-based MRI should be performed unless contraindicated by the presence of an implanted pacemaker, defibrillator, other indwelling device, or medical condition (i.e., renal impairment that would prevent the use of gadolinium contrast agents, in accordance with the site guidelines). In cases of renal impairment, non-gadolinium contrast agents may be used at the discretion of the consulting radiologist or in accordance with the site guidelines. If MRI is contraindicated, a CT scan may be used. 17. Where possible, a 6-minute walk should be performed at approximately the same time during the day for the initial and subsequent assessments. During follow-up assessments, the 6-minute walk test and cardiopulmonary exercise tests should not be performed on the same day whenever possible. 18. Administer rituximab premedication, acetaminophen, and diphenhydramine 30-60 minutes before rituximab infusion. For further details, please refer to the pharmacy manual. 19. Corticosteroids will be administered daily from day 1 to week 8 at a dose of prednisone (IV or PO) 1 mg / kg (or methylprednisolone or dexamethasone equivalent). Corticosteroid tapering will be initiated at week 8 (day 56) after administration of the investigational drug and discontinued (d / c) by 3 months after administration of the investigational drug. Longer tapering or initiation of tapering before or after day 56 is permitted at the discretion of the principal investigator in charge of treatment using an investigational medical monitor. Supportive medications for corticosteroid administration may be provided according to the standards of the clinical trial site.

[0236] Serum titer of anti-AAV9 neutralizing antibodies To determine the anti-AAV9 neutralizing antibody titer in the serum, blood samples will be collected at screening, day 1, week 2, week 4, week 8, month 3, month 6, month 12, month 24, and month 36, according to the event schedule (Figures 10A-10D). Patients with an anti-AAV9 neutralizing antibody titer greater than 1:40 are not eligible to participate in the clinical trial.

[0237] Liver ultrasound In addition to clinical laboratory evaluation of bilirubin, PT / INR, and transaminase levels, liver ultrasound should be performed at screening to assess findings consistent with cirrhosis or other liver failure. Subsequent (post-infusion) ultrasound may be performed if clinically necessary.

[0238] Safety evaluation Vital signs The vital signs to be measured include systolic / diastolic blood pressure, pulse rate, respiratory rate, pulse oximetry, and body temperature, and will be performed according to the standards of the clinical trial site. Vital signs will be measured at all clinical trial visits according to the event schedule (Figures 10A-10D).

[0239] Height and weight Height (cm) will be measured at the time of screening and then once a year thereafter. Weight (kg) will be measured according to the event schedule (Figures 10A to 10D): at the time of screening, on day -1, once a week from week 1 to week 8, once every three months (from month 3 to month 12), and once every six months (from month 12 to month 36). The weight measurement taken on day -1 will be used to calculate the patient's dosage.

[0240] Clinical and physical examinations A complete physical examination (general condition, overall appearance; head, eyes, ears, nose, and throat; cardiovascular; skin, abdomen; urogenital; lymph nodes; liver; musculoskeletal; respiratory; and neurological) will be performed according to the event schedule (Figures 10A to 10D) at the time of screening, once daily from day -14 and day -7, day -1, day 0, and days 1 through 7, once weekly from week 2 through week 8, once every three months (from month 3 to month 12), and once every six months (from month 12 to month 36).

[0241] Hematology, coagulation tests, and chemistry Blood samples for clinical testing, including CBC and fractionation, coagulation tests, and chemistry, shall be prepared as specified below and in the event schedule (Figures 10A-10D). Clinical testing shall be performed and reviewed by the principal investigator or a qualified authorized person (e.g., a medical assistant, nurse practitioner). The following clinical test parameters shall be determined. Hematology: Hemoglobin, hematocrit, red blood cell (RBC) count, mean cell volume (MCV), mean cellular hemoglobin concentration (MVHC), platelets, white blood cell (WBC) count, and fractions including neutrophils, lymphocytes, monocytes, eosinophils, and basophils. -Chemistry: Sodium, potassium, chloride, carbon dioxide (or bicarbonate), blood urea nitrogen (BUN), creatinine, glucose, ALP, ALT, AST, bilirubin, GGT, calcium, magnesium, and phosphorus.

[0242] Hematological and chemical evaluations shall be performed at the time of screening, on day -1, once daily from day 1 to day 7, up to three times per week from week 2 to week 4 (hematology) or week 8 (chemistry), once every three months (from month 3 to month 12), and once every six months (from month 12 to month 36). If serum creatinine is greater than 1.5 × ULN at the time of screening, creatinine clearance (CrCl) may be calculated, and CrCl shall be calculated using the MDRD formula at 50 mL / min / 1.73 m². 2 In the case of [specific condition], the patient is considered eligible. - Coagulation tests: PT (and / or INR), aPTT, D-dimer, thrombin-antithrombin complex (TAT), and fibrinogen. Evaluations are performed at screening, on day 1, day 2, day 4, day 7, once a week from week 2 to week 8, once every three months (from month 3 to month 12), and once every six months (from month 12 to month 36). - Complement: C3, C4, and sC5b-9 membrane invasion complex.

[0243] C3 and C4 evaluations will be performed at screening, on day -1, day 1, day 3, day 5, day 7, up to three times per week from week 2 to week 8 (from month 3 to month 12), and once every six months (from month 12 to month 36). sC5b-9 evaluations will be performed at screening, on day -1, once daily from day 1 to day 7, up to three times per week during week 2, once daily from week 3 to month 8, at month 3, and at month 6. Additional clinical tests may be performed at the discretion of the principal investigator.

[0244] Cardiac Serology Blood samples for cardiac serological testing are collected according to the event schedule (Figures 10A-10D). The parameters to be measured include the following: BNP was collected at the time of screening; on day 1; once between weeks 2, 4, 6, and 8; once every 3 months (from month 3 to month 12); and once every 6 months (from month 12 to month 36). CK-MB was collected during screening, on day -1, day 7, once a week from week 2 to week 8, once every 3 months (from month 3 to month 12), and once every 6 months (from month 12 to month 36). High-sensitivity troponin levels were collected at the time of screening, on day 1, day 2, day 4, day 7, once a week from week 2 to week 8, once every 3 months (from month 3 to month 12), and once every 6 months (from month 12 to month 36).

[0245] Urine test Urine samples for specific gravity, pH, protein, glucose, ketones, blood, and urinary leukocyte esterases are collected once during the following periods, according to the event schedule (Figures 10A-10D): at screening; on day 7, week 4, week 8; and at 12, 24, and 36 months.

[0246] immunogenicity Blood samples for immunogenicity testing are collected in whole blood and serum to determine humoral (antibody) and cellular (T lymphocyte) anti-AAV9 and anti-LAMP-2B protein activity. IgG and IgM are also collected according to the event schedule (Figures 10A-10D). Blood samples for antibody evaluation are collected once at screening; day 7; weeks 2, 4, 8, 3 months, 6 months, 12 months, 24 months, and 36 months. Blood samples for cytological evaluation are collected once at screening; weeks 4, 8, 3 months, 6 months, 12 months, 24 months, and 36 months. Blood samples for IgG and IgM evaluation are collected once at screening; day 1, 2, 4, 7; weeks 4, 8, 3 months, and 6 months.

[0247] Vector detachment Blood (plasma), saliva, urine, and stool samples for evaluating vector particle detachment are collected once during the event schedule (Figures 10A-10D): at screening; on day 3; and at weeks 2, 4, 8, 3, 6, and 9. Evaluation of each fluid / substance is continued as instructed until two negative evaluations are obtained for a given fluid / substance, or when the vector level reaches a low or negligible level and becomes level. At that point, no further evaluation is necessary.

[0248] Adverse events All adverse events (AEs) arising from informed consent and, where applicable, the submission of a consent form will be recorded. This includes AEs voluntarily reported by the patient, AEs observed by the principal investigator, and AEs identified by the principal investigator in response to open-ended questions during scheduled site visits. Systematically recorded information will include the type of AE, onset and recovery dates, severity, and perceived relationship to experimental therapy. The severity of each AE will be assessed based on the NCI CTCAE 5.0.

[0249] Effectiveness evaluation Electrocardiogram (ECG) A 12-lead ECG will be performed according to the event schedule (Figures 10A to 10D): at the time of screening, on day -1, on day 1, once a week from week 2 to week 8, once every three months (from month 3 to month 12), and once every six months (from month 12 to month 36).

[0250] Echocardiogram Echocardiography will be performed according to the event schedule (Figures 10A-10D) at screening, week 4, week 8, every three months (from month 3 to month 12), and every six months (from month 12 to month 36). Components of the echocardiogram include assessment of left ventricular ejection fraction (LVEF), left and right ventricular dimensions (e.g., LV end-systolic and end-diastolic dimensions, volume, and index, septal and posterior wall thickness, and LV outflow tract dimensions), assessment of concentric hypertrophy and diastolic pattern, assessment of valve stenosis and regurgitation, assessment of wall motion abnormalities, pulmonary artery pressure, size and changes in the IVC with respiration, pericardium, LV mass, left atrial (LA) diameter and volume, isovolumetric relaxation time, Doppler velocity measurements, longitudinal global strain, and classification of the left ventricular outflow tract (LVOT).

[0251] New York Heart Association (NYHA) classification The NYHA classification, as shown in Table 4, provides a simple way to classify the degree of heart failure according to the severity of symptoms. Patients are classified into one of four categories based on the level of physical activity limitations. NYHA assessments are performed at all trial visits except the baseline visit, according to the event schedule (Figures 10A-10D).

[0252] (Table 4) TIFF2023552443000030.tif62147

[0253] Cardiac magnetic resonance imaging Gadolinium-based MRI will be performed unless contraindicated by the presence of an implanted pacemaker, defibrillator, other indwelling device, or medical condition (i.e., renal impairment that would prevent the use of gadolinium contrast agents, in accordance with the site guidelines). In cases of renal impairment, a non-gadolinium contrast agent (i.e., fermoxyl) may be used at the discretion of the consulting radiologist or in accordance with the site guidelines. Evaluations will be performed during screening, at week 8, month 6, month 12, month 18, month 24, month 30, and month 36, in accordance with the event schedule (Figures 10A-10D).

[0254] Cardiac MRI involves IV injection of gadolinium and acquisition of multiple sequences over an estimated total scan time of 30–40 minutes. Assessment includes LVEF, LV mass indexed against body surface area (BSA), maximum LV wall thickness, z-score against maximum wall thickness, LV end-diastolic and end-systolic volume, LA diameter, volume, and volume index, assessment of late gadolinium enhancement (LGE), and LGE pattern (Raja2018). Additional assessments include resting perfusion myocardial flow (MBF), extracellular volume (T1 maps before and after gadolinium injection), and right ventricular ejection fraction (RVEF). If MRI is contraindicated, cardiac CT scan with venous contrast may be used instead.

[0255] 6-minute walk test The 6MWT is a practical and simple test that requires a 100-foot corridor and does not require any technical exercise equipment or advanced training. The test measures the distance a patient can walk quickly on a flat, hard surface in six minutes, and is therefore a quantitative assessment of important daily activities that are gradually impaired in patients with DD. During the screening visit, patients must be able to walk more than 150 meters unassisted during the 6MWT to qualify for participation in the trial. In addition, patients in Loss Class I are considered eligible if they are unable to walk at least 450 meters unassisted during the 6MWT.

[0256] The 6MWT will be completed at screening, week 8, month 3, month 6, month 12, month 18, month 24, month 30, and month 36, according to the event schedule (Figures 10A-10D). Whenever possible, each evaluation should be performed at the same time of day during trial follow-up. The same instructions should be given to each patient at the specified intervals during the 6MWT at each evaluation point. The 6MWT should be performed on a different day than the CPET at the point where both evaluations are scheduled. This evaluation should be performed twice, approximately 24 hours apart, at each trial visit.

[0257] Cardiopulmonary exercise test Cardiopulmonary exercise testing (CPET), including assessment of oxygen consumption (VO2), will be performed at baseline, week 8, month 6, month 12, month 18, month 24, month 30, and month 36, according to the event schedule (Figures 10A-10D). CPET will involve assessment on a cycle ergometer or treadmill, including resting no-load exercise and incremental incline exercise designed to result in a total exercise time of 8-12 minutes, where exhalation is measured to determine oxygen consumption and carbon dioxide production. Measurements will include vital signs, lung index (including maximal effort), ventilation threshold measurement (including respiratory exchange ratio and minute ventilation to carbon dioxide production), peak exercise measurement (including peak vital signs and peak VO2), anaerobic threshold measurement (including VO2), and recovery assessment. At each point in time that dictates both assessments, CPET should be performed on a different day from the 6MWT.

[0258] Pulmonary function test Pulmonary function tests (PFT) are evaluated at baseline, 12 months, 24 months, and 36 months according to the event schedule (Figures 10A-10D) to allow for assessment of both lung and diaphragmatic muscle capacity. PFT evaluation includes measurement of flow volume (including FVC and FEV1), vital capacity, and diffusion capacity (including DLCO2). Maximum inspiratory and expiratory pressure are also evaluated.

[0259] Right heart catheterization and endocardial myocardial biopsy Right heart catheterization and endocardial biopsy will be performed at baseline, week 8, week 6, month 12, and month 36, according to the event schedule (Figures 10A-10D). Catheterization and biopsy will be performed by an interventional cardiology team with expertise in these procedures. The use of anesthesia during right heart catheterization and endocardial biopsy will be based on the guidelines of the clinical trial site and the clinical judgment of the principal investigator. Risks associated with anesthesia are described in the product insert.

[0260] Right heart catheterization based on hemodynamic evaluation Right heart catheterization is performed to enable evaluation of cardiopulmonary hemodynamic parameters. The hemodynamic parameters to be evaluated include right atrial pressure and pulmonary artery pressure, pulmonary artery wedge pressure, mixed venous oxygen saturation, cardiac output and cardiac index (Fick formula), pulmonary capillary wedge pressure, pulmonary vascular resistance, and pulmonary hypertension.

[0261] Endocardial myocardial biopsy Endocardial myocardial biopsy is performed by inserting a central venous access catheter into the right ventricle and performing catheter-mediated biopsy of the interventricular septum, requiring approximately 3 to 5 samples per procedure.

[0262] Biopsy allows for the evaluation of any therapy-related changes in LAMP2B gene / protein expression and DD-related cardiomyopathy (i.e., autophagynophagocytic vacuoles, myofibrils) changes. Recommendations for subsequent right heart catheterization and endocardial biopsy should be assessed based on the degree of observed histological changes and LAMP-2B expression in Phase I, and by including potential correlations between cardiomyocytes and histological changes with parameter improvements from minimally invasive assessments, including LAMP-2B expression from skeletal muscle biopsy, serum LAMP-2B levels, and other serological and radiographic parameters of cardiomyopathy and CHF.

[0263] Skeletal muscle biopsy Skeletal muscle biopsies will be performed to assess LAMP2B gene / protein expression, both to confirm the potential of the investigational drug to prevent or reverse the musculoskeletal component of DD and to evaluate whether LAMP2 skeletal muscle can be a potentially viable substitute for LAMP2 cardiac gene correction and protein expression. Incisional biopsies of the vastus lateralis muscle will be performed at baseline, 8 weeks, 6 months, 12 months, and 36 months to enable evaluation of the parameters detailed above. Biopsies at consecutive evaluations (i.e., baseline and 8 weeks post-treatment) will be performed alternately on the contralateral muscle (i.e., the right bundle branch at baseline and the left bundle branch at post-treatment evaluation) to minimize potential procedure-related side effects. In subsequent (Phase II) trials, the need for muscle biopsies will be assessed based on the histological changes and degree of LAMP-2B expression observed during Phase I trials, as well as the correlation of gene / protein expression between endocardial myocardium and skeletal muscle. The use of needle biopsies during subsequent trials will also be considered. The use of anesthesia during skeletal muscle biopsy procedures is based on the guidelines of the clinical trial site and the clinical judgment of the principal investigator. Risks associated with anesthesia are described in the product insert. If necessary, skeletal muscle biopsy may be performed in conjunction with endocardial myocardial biopsy, and anesthesia or sedation may be limited.

[0264] Neurocognitive assessment For patients aged 16 years or older who are considered to have normal or near-normal (mildly limited) cognitive function, neurocognitive assessment includes the following components: • Wechsler Adult Intelligence Scale (WAIS-IV). • The Vineland Adaptive Behavior Scale, 3rd Edition (Vineland-3).

[0265] Patients aged 16 and older with more limited cognitive function will not be assessed using the WAIS-IV. These patients will be assessed using the following components: • The Vineland Adaptive Behavior Scale, 3rd Edition (Vineland-3). ·Differential Ability Scales (DAS-II).

[0266] The most appropriate assessment will be made by the principal investigator in collaboration with a psychologist / neurocognitive assessment specialist.

[0267] For patients under 18 years of age, neurocognitive assessment includes the following elements: • WAIS-IV (for individuals aged 16 or 17 with normal or near-normal cognitive function). • Vineland-3 Parent / Career Evaluation. ·Differential Ability Scale (DAS-II).

[0268] Neurocognitive assessments will be conducted at baseline, 12 months, 24 months, and 36 months, according to the event schedule (Figures 10A-10D). These should be performed in the same order at each assessment whenever possible. A brief description of each assessment is provided below.

[0269] Wechsler Adult Intelligence Scale (WAIS-IV) The WAIS-IV provides a concise and reliable measure of cognitive ability. It consists of a set of standardized questions and tasks to assess an individual's potential for purposeful and useful behaviors. It is designed to measure primary intelligence. The test provides standardized scores for a total estimate of general cognitive ability, verbal comprehension, and nonverbal comprehension.

[0270] Vineland Adaptive Behavior Scale, 3rd Edition (Vineland-3) The Vineland-3 is a standardized measure of adaptive behavior, representing what people do to function in daily life. While competency measurements focus on what a subject can do in a test setting, the Vineland-3 focuses on what they actually do in daily life. Because it is a standards-based measure, it compares a subject's adaptive functioning to others of the same age. This is a powerful tool for supporting the diagnosis of intellectual and developmental disabilities. The Vineland-3 Parent / Caregiver Interview Form measures an individual's adaptive behavioral functioning across four domains: communication, daily living, socialization, and motor skills (from birth to 90 years of age).

[0271] Differential Ability Scale (DAS-II) The DAS-II is a comprehensive, individualized clinical tool for assessing cognitive abilities important for learning. It is administered to children aged 2 years 6 months (2:6) to 17 years 11 months (17:11) across a wide range of developmental levels. The test provides standardized scores for overall conceptual comprehension, verbal comprehension (verbal concepts and knowledge), nonverbal comprehension (complex nonverbal inductive reasoning requiring mental processing), and spatial comprehension (complex visual processing).

[0272] Neuromuscular assessment Neuromuscular assessments will be performed at baseline, 8 weeks, 6 months, 12 months, 24 months, and 36 months. This includes mandatory timed neuromuscular activity tests, including the following: Getting up from the floor, • Four-step stair climbing • Walking / running 10 meters, • Timed Up and Go (TUG), and • Northstar Walking Ability Assessment Test.

[0273] Ophthalmic examination Ophthalmic examinations will be performed at baseline, 12 months, 24 months, and 36 months, according to the event schedule (Figures 10A-10D). This includes retinal evaluation by direct ophthalmoscopic examination / fundus examination, fundus photography, optical coherence tomography, tomography, autofluorescence, and electroretinography.

[0274] Patient-reported outcomes / quality of life (PRO / QOL) The PRO / QOL scales used in this study include the KCCQ-12 and PedsQL. Assessments are collected at baseline, at 8 weeks, every 3 months (from 3 to 12 months), and every 6 months (from 12 to 36 months), according to the event schedule (Figures 10A to 10D).

[0275] Effectiveness evaluation The evaluation of clinical efficacy endpoints includes the following assessments, which are performed during the first month and year after administration of the investigational drug, according to the event schedule (Figures 10A to 10D). • CPET including VO2 evaluation. • 6MWT (distance) evaluation. • Endocardial myocardial biopsy (performed by insertion of a central venous access catheter into the right ventricle) to evaluate DD-related histological abnormalities and the presence of the LAMP2B gene / RNA / protein in cardiomyocytes. • Gadolinium-enhanced cardiac MRI (unless contraindicated by the presence of an implanted pacemaker, defibrillator, other indwelling device, or medical condition). • Echocardiogram. • Patients who choose to have their overall survival assessed and discontinue other components of follow-up (this is strongly discouraged unless their health has deteriorated to a degree that would contraindicate it) will be offered the option to remain in contact with the trial staff for assessment of their overall health and survival. • Evaluation of the need for subsequent hospitalization due to heart transplantation, LVAD, implantation of an implantable cardioverter-defibrillator or pacemaker, electrophysiological resection for cardiac conduction abnormalities, or CHF.

[0276] statistical methods A sample size of up to 3 patients per administration cohort and expansion to up to 6 patients (1 of 3 patients in the case of DLT) is considered a standard safe approach for dose evaluation of novel investigational drugs. Assuming a true DLT rate of 5% or less, the probability of dose escalation stopping based on a given cohort is 3% (i.e., observed in 2 or more DLT patients). Assuming a true DLT rate of 50%, the probability of dose escalation stopping based on a given cohort is 83%.

[0277] Number of patients to be registered 11-23 patients (Cohort 1 enrolled 3 patients according to the previous protocol version)

[0278] Test group The evaluation population includes all test populations, and the investigational drug is administered within the range of the test population. Additional evaluation populations include adult patients (including both those 18 years and older and those 15–17 years old) and a pediatric population including those 8–14 years old.

[0279] Example 6: Results of Phase I Test The results of the Phase I trial showed strong trends in many key clinical biomarkers and endpoints.

[0280] DD is a genetically inherited cardiomyopathy, and its characteristics and progression differ from those of typical adult cardiomyopathy. The majority of patients are well compensated for functional impairment until later in the disease course, and measurements such as LVEF and 6MWT may be normal or mildly abnormal until the cardiomyopathy progresses. Mild improvement or stabilization of disease-related abnormalities is desirable in this patient population and likely represents an improvement over the emerging natural course, which may be accompanied by stabilization and / or improvement of clinical biomarkers that have been shown to correlate with progression in natural course studies.

[0281] Low-dose and high-dose adult and adolescent cohorts over 15 years old (6.7 × 10⁻¹⁰ 13 GC / kg and 1.1 × 10⁻⁶ 14 Clinical data (GC / kg) demonstrated the effectiveness of the treatment. The data included the following: 1. Confirmation of sustained LAMP2 protein expression in the primary target organ. 2. Demonstration at the cellular level of improvement in morphological DD characteristics. 3. Improvement and / or stabilization of major cardiac parameters, including BNP (decrease in each of four patients with long-term follow-up, including a 75%–79% reduction from baseline in two low-dose patients with confirmed immunosuppressive regimen compliance). 4. Improvement in NYHA class was observed in 3 out of 4 adults (immunosuppression was confirmed in the low-dose and high-dose cohorts, and stabilization was observed in other low-dose patients; each of the 4 patients showed stabilization to mild improvement in the 6MWT). 5. Self-reported improvements in quality of life and function in all subjects treated with low doses.

[0282] Stable LAMP2B expression data (Figure 14) are accompanied by demonstrable and favorable changes in myocardial structure and recovery of pathological DD features, as assessed by electron microscopy of endocardial biopsy specimens at pre- and post-treatment time points. These are illustrated in Figure 14, which shows myocardial tissue from subject 1005. Similar to these findings in a mouse knockout model, the pre-treatment biopsy showed numerous extensive autophagocytic vacuoles and marked myofibrillary disorder, making distinct muscle elements minimally distinguishable. A similar endocardial biopsy at 8 weeks post-treatment showed a marked reduction in autophagocytic vacuoles and recovery of myofibril structure with extensive and clearly defined striae. These findings were confirmed at a later time of 9 months, suggesting that molecular and histological recovery was maintained.

[0283] Further data on relevant cardiac clinical markers in the low-dose cohort also indicate either improvement or stabilization of key cardiac function markers, including type B natriuretic peptide (BNP) (Table 5), creatine kinase myocardial bands (MB), and cardiac output as measured by invasive hemodynamics. Importantly, the observed improvement in BNP from baseline (79% for 1002 and 75% for 1005 at 18 months and 15 months, respectively) was considered highly relevant and promising by experts in the field, given the strong correlation between natriuretic peptide and prognosis in heart failure (Januzzi et al. J Investig Med. 2013 Aug;61(6):950-955).

[0284] One of the most significant parameters of clinical benefit is the patient's level of function, particularly in relation to heart failure, the ability to tolerate physical activity as part of daily life. Therefore, assessment items such as the New York Heart Association (NYHA) classification are considered strong measures of clinical improvement related to overall global patient functional status (Russel et al. Am Heart J. 2009 Oct;158(4Suppl):S24-S30). Of the four subjects with long-term follow-up in the low-dose and high-dose cohorts, three showed improvement from NYHA classification II to I (Table 5), and the remaining one maintained a stable level of II, which is significant and highly inconsistent with the natural course of DD.

[0285] At the latest long-term evaluation in November 2021, all three patients showed stabilization and / or slight improvement in their 6MWT results (Table 5). In addition, as reported in the PI interview at the latest visit, all subjects reported feeling generally well and did not report any limitations in their activities. Subjects 1002 and 1005 also reported no activation of their implanted cardioverter-defibrillators since receiving RP-A501.

[0286] (Table 5) TIFF2023552443000031.tif157146

[0287] A characteristic feature of Danon cardiomyopathy in men is, in particular, increased wall thickness due to hypertrophy and associated diastolic dysfunction. As shown in Figures 15A–15B, four out of five patients evaluable at high and low doses showed either stable or decreased wall thickness as measured by serial echocardiography. In some subjects, the decrease in wall thickness was accompanied by a slight improvement or stabilization of ejection fraction, which is a late sign of Danon disease (Figure 15B). In addition to echocardiographic parameters, invasive hemodynamics allowed for the measurement of pulmonary capillary wedge pressure, a measure of diastolic dysfunction and left ventricular filling pressure. Consistent with other cardiac parameters, serial wedge pressure and cardiac output / stroke volume in treated patients showed either improvement or stabilization (Figures 15C–15D). Considering the natural course of the disease, this is in contrast to the normal progression in these patients.

[0288] Table 6 shows that RP-A501 demonstrated a stable cardiac vector copy number (VCN).

[0289] (Table 6) TIFF2023552443000032.tif90148

[0290] Table 7 shows endocardial LAMP2B protein expression as determined by immunohistochemistry (IHC).

[0291] (Table 7) TIFF2023552443000033.tif104148

[0292] Table 8 shows the endocardial LAMP2B Western blot protein expression.

[0293] (Table 8) TIFF2023552443000034.tif100147

[0294] As detailed above for the low-dose and high-dose cohorts of the Phase I trial, all relevant cardiac assessments, including serum heart failure markers, invasive hemodynamic output measurements, echocardiographic evaluations, and overall functional assessments, demonstrate disease improvement, even representing a stable or positive outcome, compared to the natural course of progressive and fatal cardiomyopathy with a median mortality of 19 years. These clinical assessments are accompanied by evidence of LAMP2 expression in the myocardium, as well as histological improvements in vacuolar pathology and myofibrils, which are characteristic of DD. For these reasons, the overall evidence, including both nonclinical and especially clinical data, overwhelmingly demonstrates the potential for direct benefit from RP-A501.

[0295] RP-A501 was generally well-tolerated at both low and high dose levels. All observed adverse events were reversible, and no sequelae persisted. Early elevations of transaminases and creatinine kinases, as well as decreases in platelets and hemoglobin, returned to baseline or eventually improved. RP-A501r-AAV dose-dependent toxicity was observed in one of two patients treated at the high dose level. The affected patient, who received the highest total dose, developed thrombotic microangiopathy (TMA), which resolved completely with supportive care, including transient hemodialysis. Across both dose levels, adverse events were reversible and nearly resolved at 3 months post-treatment with the adjusted immunosuppressive regimen.

[0296] All references, articles, publications, patents, patent gazettes, and patent applications cited herein are incorporated in their entirety by reference for all purposes. However, no reference to any reference, article, publication, patent, patent gazette, or patent application cited herein shall be considered, nor any form of, an endorsement or proposal to constitute valid prior art or to form part of the common general knowledge in any country worldwide.

Claims

1. 1. A unit dose, pharmaceutical composition, or composition for use in treating Danon disease in a subject identified as suffering from or at risk for Danon disease and / or identified as having an inactivating mutation in one or more isoforms of the LAMP-2 gene, comprising: a therapeutically effective amount of a recombinant adeno-associated virus (rAAV) virion comprising a capsid and a vector genome; The vector genome comprises a polynucleotide sequence encoding a LAMP-2 protein, preferably a LAMP-2B protein; A unit dose, pharmaceutical composition, or composition for said use.

2. The therapeutically effective amount is about 2×10 14 2. The unit dose, pharmaceutical composition, or composition for use of claim 1, wherein the vector genome (vg) is less than about 1.5x1014 vg, less than about 1x1014 vg, at least about 1x1012 vg, at least about 1x1013 vg, about 6.7x1013 vg, about 1.1x1014 vg, or about 2.0x1014 vg.

3. A unit dose, pharmaceutical composition, or composition for use as described in claim 1 or 2, characterized in that the pharmaceutical composition is used in combination with an effective amount of (i) tacrolimus or sirolimus; (ii) rituximab; (iii) eculizumab; (iv) a corticosteroid, optionally selected from dexamethasone, methylprednisolone, or prednisone; or (v) any combination of (i)-(iv).

4. A unit dose, pharmaceutical composition, or composition for use as described in claim 3, wherein the pharmaceutical composition is used in combination with an effective amount of eculizumab, and the subject is at risk of atypical hemolytic uremic syndrome (aHUS), optionally, aHUS resulting in reversible thrombocytopenia and / or acute kidney injury (AKI).

5. A unit dose, pharmaceutical composition, or composition for use as described in claim 3, characterized in that the pharmaceutical composition is used in combination with an effective amount of a corticosteroid prior to use in combination with an effective amount of tacrolimus.

6. 6. The unit dose, pharmaceutical composition or composition for use according to any one of claims 1 to 5, wherein the subject is optionally a young subject aged between 8 and 14 years and / or 15 to 17 years, optionally a pediatric subject aged between 0 and 8 years, or optionally an adult subject aged 18 years or older.

7. 7. The unit dose, pharmaceutical composition, or composition for use according to any one of claims 1 to 6, wherein the therapeutically effective amount of the AAV is administered intravenously, by direct cardiac injection, or by intraperitoneal injection.

8. The pharmaceutical composition comprising: a) transduction of cardiomyocytes and / or skeletal muscles with said AAV; b) optionally expression of an exogenous ribonucleic acid polynucleotide encoding LAMP-2B and / or expression of an exogenous LAMP-2B protein in cardiomyocytes and / or skeletal muscles; c) correction or amelioration of one or more Danon disease-associated histological abnormalities, optionally autophagic vacuoles or myofibrillar disarray; d) correction or improvement of cardiomyocyte molecular marker expression; and / or e) Correction or improvement of cardiomyocyte histology 8. A unit dose, pharmaceutical composition or composition for use according to any one of claims 1 to 7, which provides one or more of the following:

9. The pharmaceutical composition comprising: a) sustained improvement or stabilization of cardiovascular pathophysiology, radiological assessments, and / or cardiopulmonary exercise / physiological parameters; b) correction of LAMP2B gene and / or protein expression; c) amelioration of Danon disease-associated histological abnormalities, and / or d) Tolerant immune response to AAV 9. A unit dose, pharmaceutical composition or composition for use according to any one of claims 1 to 8, which provides one or more of the following:

10. The pharmaceutical composition comprising: a) low incidence and / or intensity of treatment-emergent adverse events (TEAEs) and SAEs; b) a low incidence of cardiac interventions, including cardiac transplantation, implantable cardioverter-defibrillator or pacemaker placement, electrophysiologic ablation of cardiac conduction abnormalities, or subsequent hospitalization for heart failure; c) a low immune response to AAV, optionally antibodies or T lymphocytes reactive to AAV and / or LAMP-2B proteins; d) low incidence and / or intensity of hepatotoxicity, optionally small changes in hepatic transaminases (AST and ALT), GGT, bilirubin, and ALP; and / or e) Low incidence and / or severity of coagulopathy based on changes from baseline in platelet count, prothrombin time (PT, or international normalized ratio (INR)), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, thrombin-antithrombin complex (TAT), and complement components (complement 3 (C3), complement 4 (C4), and serum membrane attack complex (sC5b-9)).

10. The unit dose, pharmaceutical composition or composition for use according to any one of claims 1 to 9, which provides one or more of the following:

11. The AAV comprises an expression cassette comprising the polynucleotide sequence encoding the LAMP-2B protein operably linked to a promoter; and (i) the polynucleotide sequence shares at least 95% identity to, comprises or consists of SEQ ID NO:2, and / or (ii) the LAMP-2B protein shares at least 95% identity to, comprises or consists of SEQ ID NO:1, A unit dose, pharmaceutical composition or composition for use according to any one of claims 1 to 10.

12. The vector genome comprises a promoter, and The promoter is a CAG promoter; or The promoter is a CAG promoter and comprises an enhancer / promoter region, the enhancer / promoter region sharing at least 95% identity to, comprising, or consisting of SEQ ID NO:22; A unit dose, pharmaceutical composition or composition for use according to any one of claims 1 to 11. (i) the expression cassette comprises, in 5' to 3' order: (a) an enhancer / promoter region comprising SEQ ID NO:22; (b) the polynucleotide sequence comprising SEQ ID NO:3 and encoding the LAMP-2B protein; (c) a 3'UTR sequence comprising SEQ ID NO: 27, and / or (d) a polyadenylation sequence comprising SEQ ID NO:

7. Including, (ii) the expression cassette is flanked by (a) a 5' ITR that comprises SEQ ID NO:11, and (b) a 3' ITR that comprises SEQ ID NO:12; or (iii) the expression cassette comprises SEQ ID NO:8; 13. A unit dose, pharmaceutical composition or composition for use according to claim 11 or 12.

14. the capsid is an AAV9 capsid; or the capsid is an AAV9 capsid, and the AAV9 capsid comprises one or more capsid proteins comprising amino acids 1-736 of SEQ ID NO:28, amino acids 138-736 of SEQ ID NO:28, or amino acids 203-736 of SEQ ID NO:28; A unit dose, pharmaceutical composition or composition for use according to any one of claims 11 to 13.

15. A kit comprising a unit dose, pharmaceutical composition or composition for use according to any one of claims 1 to 14 and instructions for use in the treatment of Danon disease.

16. 16. The kit of claim 15, further comprising one or more unit doses, pharmaceutical compositions, or compositions comprising one or more of rituximab, tacrolimus, eculizumab, and a corticosteroid.